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13.1
Introduction
It has been estimated that genitourinary malignancies
will account for 25% of new cancer diagnoses in the
United States in 2005 (Jemal et al. 2005).While the inci-
dence ofmany of thesemalignancies has increased over
the past two decades, the mortality rates appear to be
decreasing. Early cancer detection combined with im-
provements in surgical and nonsurgical oncologic ther-
apy account for these trends. Although not common,
newly diagnosed cancer patients occasionally present
in an emergent, life-threatening manner that warrants
immediate medical or surgical intervention. As the
prevalence of genitourinary malignancies continues to
expand, additional patients can be expected to develop
disease or treatment-related complications. This chap-
ter will serve to review the diagnosis and management
of oncologic emergencies as they pertain to the urolo-
gist.
13.2
Spontaneous Perinephric Hemorrhage
Renal cell carcinoma (RCC) is the fourthmost common
genitourinary malignancy in the United States, with an
estimated 36,000 new cases expected in 2005 (Jemal et
al. 2005). In contrast to years past, themajority of cases
are now diagnosed incidentally due to the widespread
availability and performance of abdominal imaging.
While presentation with the classic triad of flank pain,
gross hematuria, and a palpable abdominal mass is
now rare (Jayson and Sanders 1998), a small propor-
tion of cases complicated by a spontaneous perinephric
hemorrhage (SPH) will demonstrate one or all of these
findings. It is difficult to estimate the true incidence of
spontaneous tumor hemorrhage since SPH is not spe-
cific to RCC and most descriptions of SPH amount to
case reports only. Nonetheless, this would appear to be
an uncommon mode of presentation for RCC. Neovas-
cularity and propensity for necrosis are possible expla-
nations for tumor rupture and hemorrhage (Hora et al.
2004).
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13.2.1
Background
Spontaneous perinephric hemorrhage represents a di-
agnostic and therapeutic challenge. Appropriate treat-
ment depends on the hemodynamic stability of the pa-
tient and a correct determination of its cause. In light of
its infrequent occurrence, management guidelines for
SPH are based on data acquired throughmeta-analyses
of case reports. Since 1933, four available meta-analy-
ses have reviewed 448 cases of SPH, 165 of which took
place after 1985 (Polkey and Vynalek 1933; McDougal
et al. 1975; Cinman et al. 1985; Zhang et al. 2002). It ap-
pears that SPH occurs with equal frequency in males
and females as well as in right and left kidneys. Flank or
abdominal pain of acute onset is themost commonpre-
senting symptom (83%–100%) (Zhang et al. 2002; Pe-
reverzev et al. 2005). Interestingly, only a minority of
SPH cases demonstrate gross or microscopic hematu-
ria (0%–19%). Up to 11% present with signs and
symptoms of hypovolemic shock indicative of a severe
retroperitoneal hemorrhage. Numerous etiologies
exist, the most common of which is neoplasm (57%–
66%), benign or malignant, followed by vascular dis-
ease (17%–26%), idiopathic hemorrhage (6.7%), and
infection (2.4%). Angiomyolipoma (AML) and RCC
represent the most common benign and malignant
neoplastic causes of SPH, accounting for 24%–33%
and 30%–33% of all cases, respectively. With such dis-
parate etiologic possibilities, accurate diagnosis is of
the utmost importance to ensure appropriate treat-
ment is provided.
Computed tomography (CT) with intravenous (i.v.)
contrast is the imaging study of choice for SPH
(Fig. 13.1). The diagnostic accuracy of CT for a peri-
nephric hematoma approaches 100%, and the reported
a b
Fig. 13.1a, b. Spontaneous right hemorrhage. a, b Contrast-enhanced CT demonstrating right renal hemorrhage into perinephric
space. No mass lesion is discernible. Patient was subsequently diagnosed with renovascular disease
sensitivity and specificity for identification of an un-
derlying mass is 57% and 82%, respectively (Zhang et
al. 2002). Contemporary series employing state-of-the-
art CT imaging technology report up to 92%diagnostic
accuracy for determination of the underlying cause of
SPH (Sebastia et al. 1997). In contrast, the sensitivity
and specificity of ultrasound (US) is 11% and 33%, re-
spectively.Magnetic resonance imaging (MRI) is an ap-
propriate substitute in cases where contraindications
to i.v. contrast exist or CT is unavailable. Diagnostic ar-
teriography is indicated if CT or MRI does not demon-
strate a mass or if a vascular etiology is suspected (Za-
goria et al. 1991). Bilateral SPH, reported in 3% of
cases, suggests a vascular diagnosis such as polyarteri-
tis nodosa (Zhang et al. 2002).
Identification of fat content (<10 Hounsfield Units)
within a renal mass on CT, although not sensitive, is a
highly specific finding for AML (Fig. 13.2) (Bosniak et
Fig. 13.2. Angiomyolipoma. CT demonstrating bilateral angio-
myolipomas with characteristic fat attenuation
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al. 1988; Lemaitre et al. 1997). In contrast, any heterog-
enous solid or cysticmass without fat should be regard-
ed as RCC until proven otherwise. Of note, tumor size
does correlate with risk of hemorrhage for AML; how-
ever, no such correlation has been shown for RCC
(Zhang et al. 2002).
13.2.2
Evaluation
At the time of presentation, a thorough history, physi-
cal examination, and determination of hemodynamic
stability should ensue. Given that flank pain arising
from SPH is commonly confused with renal colic, a
noncontrast CT of the abdomen and pelvis is often per-
formed. In fact, a contrast-enhanced CT is the first-line
study and should be obtained in the event that a non-
contrast CT or US suggests the presence of a retroperi-
toneal hematoma. Laboratory studies should include a
complete blood count (CBC), electrolytes, blood urea
nitrogen (BUN), creatinine, and a coagulation profile.
13.2.3
Treatment
Themanagement of SPH is similar to that of renal trau-
ma wherein conservative measures are first-line and
nephrectomy is reserved as an option of last resort
(Santucci and Fisher 2005). Initial steps are directed to-
ward maintaining hemodynamic support through i.v.
hydration and blood and blood product replacement as
necessary. Bed rest is instituted along with periodic
monitoring of vital statistics and serum hemoglobin in
those patients who are hemodynamically stable. Unsta-
ble patients or those in whom the hemoglobin contin-
ues to decrease despite repeated transfusions require
diagnostic arteriography and selective embolization.
Only patients who remain unstable or continue to bleed
despite embolization need undergo open nephrectomy.
Partial nephrectomy remains an option in the early pe-
riod but should be restricted to patients with a solitary
kidney or those with a small (<4 cm), easily identifi-
able exophytic mass whose hemodynamic parameters
do not prohibit an extended procedure. Seven percent
of patients with a renalmass in available series have un-
dergone early partial nephrectomy in the setting of
SPH (Zhang et al. 2002). Unfortunately, no data on local
recurrence is available at this time.
Patients with hemodynamic stability including
those responding to conservative measures, including
embolization, require inpatient monitoring and symp-
tomatic treatment only. Ambulation and subsequent
hospital discharge can be initiated when vital signs and
hemoglobin remain stable for 24 h and gross hematu-
ria, if present, has resolved. Given the 25% risk of un-
derlying malignancy, repeat abdominal imaging with
CT scan should be performed in 1–3months (Zhang et
al. 2002; Yip et al. 1998). If a mass suggestive of RCC is
identified at presentation or in follow-up, definitive
treatment can be performed on an elective basis.
13.3
Hypercalcemia of Malignancy
Hypercalcemia is the most common paraneoplastic
syndrome of malignancy (Fojo 2005). Among genito-
urinarymalignancies, it ismost frequently identified in
association with RCC (3%–25%) (Zekri et al. 2001;
Walther et al. 1997; Papac and Poo-Hwu 1999; Skinner
et al. 1971). In comparison, hypercalcemia is an un-
common manifestation of prostate cancer and transi-
tional cell carcinoma (Coleman 1997). The incidence of
hypercalcemia in RCC correlates with the stage of the
primary tumor as well as with the presence or absence
of bone metastases (Fahn et al. 1991). Hypercalcemia
typically occurs late in the course of disease and has
demonstrated independent significance as a poor prog-
nostic factor in patients with advanced RCC (Motzer et
al. 1999).
13.3.1
Pathophysiology
Two pathogenic mechanisms are involved in the gener-
ation of hypercalcemia: (1) focal osteolytic bone de-
struction secondary to bonemetastases and (2) uncou-
pling of bone turnover secondary to tumor-secreted
humoral factors. Focal bone destruction by metastases
involves the paracrine secretion of various cytokines
that stimulate local osteoclasts and inhibit osteoblasts.
Although this mechanism certainly contributes to hy-
percalcemia, it appears that systemic factors play a
more important role. Malignant hypercalcemia caused
by the production of humoral factors is often referred
to as humoral hypercalcemia of malignancy (HHM).
The humoral factor most commonly associated with
HHM, including that of RCC, is parathyroid hormone-
related protein (PTHrP) (Burtis et al. 1990; Mundy
1990). PTHrP causes hypercalcemia through bone re-
sorption, as well as through renal calcium reabsorption
(Rosol and Capen 1992). Partial sequence homology
between PTHrP and parathyroid hormone (PTH) helps
to explain themechanisms by which this occurs. Unlike
primary hyperparathyroidism, PTH levels are often
normal or suppressed in cases of HHM (Walther et al.
1997; Flombaum 2000). Interleukin-6 (IL-6) and pros-
taglandin (PG), both of which stimulate osteoclast ac-
tivity, represent additional humoral factors involved in
HHM (Papac and Poo-Hwu 1999).
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13.3.2
Presentation
The most common presenting symptoms of hypercal-
cemia are nonspecific and include fatigue, anorexia,
nausea, and constipation. Through the induction of an
osmotic diuresis and inhibition of antidiuretic hor-
mone activity, hypercalcemia also causes polyuria and
progressive dehydration. Not uncommonly, patients
are found to have acute or chronic renal insufficiency at
the time of presentation. Neurologic symptoms such as
weakness, lethargy, and disorientation may progress
into seizures, coma, and even death if treatment is de-
layed. Symptom severity depends upon the degree of
hypercalcemia and the rate at which it develops.
13.3.3
Evaluation
Appropriate treatment of hypercalcemia depends upon
the symptom severity, serum calcium level, renal func-
tion, and overall health status of the patient. Tumor
stage and oncologic prognosis are also important and
must be taken into consideration when formulating a
management plan. Laboratory investigations include a
CBC, serum electrolytes, ionized and total serum calci-
um, albumin, BUN, and serum creatinine. Serum mag-
nesium should also be measured since hypercalcemia
commonly induces renal magnesium wasting through
actions exerted at the loop of Henle. Assays for PTHrP
are available; however, the utility of this test is ques-
tionable at present. Perhaps in cases without a defini-
tive diagnosis of malignancy, PTHrP and PTH levels
should both be evaluated.
13.3.4
Treatment
Asymptomatic patients withmild tomoderately elevat-
ed serum calcium ( e 3.25 mmol/l, e 14 mg/dl) do not
require immediate treatment as an inpatient (Fojo
2005). Rather, medical therapy may be instituted on an
outpatient basis with periodic monitoring of serum
calcium and renal function. Symptomatic patients, or
those with a serum calcium level above 3.25 mmol/l
(>14 mg/dl) indicating severe hypercalcemia require
hospital admission and immediate intervention. The
traditional andmost basic treatment for hypercalcemia
is i.v. hydration with isotonic saline. By increasing
urine calcium excretion, hydration results in a rapid,
yet modest (0.5 mmol/l) reduction in serum calcium
levels. Renal function can also be expected to improve
as the prerenal component of dysfunction is corrected.
Hydration is generally begun with the infusion of 1–2 l
of isotonic saline over 1–4 h (Flombaum 2000). Total
volumes and rate of delivery will depend on the hydra-
Table 13.1.Treatment options for hypercalcemia ofmalignancy
Treatment Dose Route Frequency
Normal saline
hydration
1–2 l IV As necessary
Furosemide 20–40mg IV As necessary
Zoledronate 4–8 mg over
5–15min
IV Every
4–6weeks
Calcitonin 4–8 IU/kg IM/SC Every 6–8 h
Gallium nitrate 100–200mg/
m2/day × 5 days
IV
Dialysis
Nephrectomy
tion and cardiovascular status of the patient. Furose-
mide, a loop diuretic that inhibits calcium reabsorption
at the loop ofHenle, can be used to augment renal calci-
um excretion. Loop diuretics should only be used when
rehydration has been completed.
Rehydration alone is often inadequate (Hosking et al.
1981). The majority of patients with hypercalcemia of
malignancy will require additional medical therapy as
outlined in Table 13.1. The cornerstone of such therapy
is the bisphosphonate group of medications. As pyro-
phosphate analogs with a high affinity for hydroxyapa-
tite, bisphosphonates concentrate in areas of high bone
turnover where they become internalized into osteo-
clasts and inhibit bone resorption (Fleisch 1991; Lin
1996; Sato et al. 1991; Fojo 2005). Three generations of
bisphosphonates are now available, each providing an
incremental improvement in potency, response dura-
tion, and toxicity profile. Etidronate, the original bis-
phosphonate, corrects hypercalcemia in 50% of pa-
tients; however, this is achieved at the expense of signifi-
cant demineralization (Singer and Minoofar 1995). The
success rate of second- and third-generation bisphos-
phonates exceeds 80% (Purohit et al. 1995; Nussbaum et
al. 1993). The current drug of choice is zoledronate, a
third-generation bisphosphonate that achieves normo-
calcemia in more than 90% of patients (Major et al.
2001). As with all bisphosphonates, this agent must be
given intravenously because of poor oral absorption.
Zoledronate usually corrects hypercalcemia within
4–10 days for a duration of 4–6 weeks. Bisphosphona-
tes are more effective against hypercalcemia arising
from focal bone destruction secondary to metastases
than against HHM. Despite potent inhibition of focal
and systemic bone resorption, bisphosphonates have no
effect on renal calcium reabsorption, which plays a
prominent role in HHM. Animal studies suggest that
bisphosphonates may cause or exacerbate renal failure;
therefore, these agents should be used with caution if
the serum creatinine exceeds 3.0 mg/dl (Stewart 2005).
Calcitonin is another treatment option for hypercal-
cemia. Reduction in serum calcium occurs primarily
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through the inhibition of osteoclast-mediated bone re-
sorption. However, supraphysiologic doses have also
been shown to improve renal calcium excretion (Lin
1996; Sato et al. 1991). Tachyphylaxis occurs within
2–3 days of repeated calcitonin dosing; therefore long-
term efficacy is not possible. The primary utility of cal-
citonin lies in the rapidity of its onset (2–6 h) (Warrell
et al. 1988). As such, calcitonin is ideally used in combi-
nation with longer-acting medications with delayed-
onset such as bisphosphonates. With the exception of
rare allergic reactions, calcitonin is considered safe and
nontoxic.
Gallium nitrate, originally developed as an antican-
cer drug, is a potent inhibitor of bone resorption (War-
rell et al. 1991). In addition to osteoclast inhibition, gal-
lium nitrate reduces serum calcium through the inhibi-
tion of both renal calcium reabsorption and PTH secre-
tion (Warrell et al. 1984;Warrell 1997). A continuous 5-
day i.v. infusion corrects hypercalcemia in approxi-
mately 80% of patients for a median duration of 8 days
(Warrell et al. 1991). Serum calcium begins to normal-
ize within hours butmaximal effect takes place after the
infusion is complete. Ten percent of treated patients ex-
perience an elevation in serum creatinine; therefore,
gallium nitrate should be used with caution in patients
with baseline renal dysfunction (Zojer et al. 1999).
Based on its lengthy administration protocol and po-
tential for nephrotoxicity, gallium nitrate is rarely used
today. It does, however, remain an important treatment
option in cases of hypercalcemia refractory to bisphos-
phonate therapy.
Dialysis is indicated in patients with severe hyper-
calcemia complicated by significant mental changes.
Patients with chronic renal failure or congestive heart
failure often cannot tolerate i.v. hydration therapy;
therefore, hemodialysis is frequently necessary in these
cases as well.
Depending on the extent of disease and the oncolog-
ic prognosis, nephrectomymay also be a consideration.
Hypercalcemia typically normalizes after nephrectomy
in cases of localized RCC (Gold and Fefer 1996; Fahn et
al. 1991). Persistence or relapse of hypercalcemia is of-
ten an indication of local recurrence or occultmetastat-
ic disease. Cytoreductive nephrectomy has been shown
to correct hypercalcemia in two-thirds of patients with
metastatic RCC; however, this effect is only temporary
(Walther et al. 1997).
13.4
Complications of Bacille Calmette-Gue´rin
Therapy
Bacille Calmette-Gue´rin (BCG) is the most effective in-
travesical agent available for the treatment of high-risk
superficial transitional cell carcinoma (TCC) of the
bladder. A live attenuated strain of the bovine tubercu-
lous mycobacterium, BCG exerts its antineoplastic ef-
fect through the stimulation of a nonspecific inflamma-
tory reaction at the bladder level. Intravesical treat-
ment is generally safe with fewer than 10% of patients
experiencing complications that require treatment be-
yond symptomatic palliation (Lamm et al. 1992, Ri-
schmann et al. 2000). Side effects can be categorized in-
to local and systemic subtypes. The most common lo-
cal toxicity is cystitis, with 80% of patients describing
varying degrees of irritative voiding symptoms (Resel
Folkersma et al. 1999). Low-grade fever (<38.5°C),
which occurs in many as one-third of patients soon af-
ter intravesical therapy, is the most frequent systemic
effect reported (Rischmann et al. 2000). The most seri-
ous toxic effects of BCG treatment include BCG-osis,
manifested as pulmonary or hepatic infection, and
BCG sepsis. Since both present with fever as an early
sign, the difficulty lies in differentiating benign, tran-
sient fever from that which heralds serious systemic ill-
ness. Fortunately, BCG-osis and BCG sepsis each affect
less than 1% of patients (Lamm et al. 1992).
In the setting of serious systemic illness following
BCG therapy, suspicion for hematogenous dissemina-
tion of mycobacteria or other urinary tract pathogens
should be high. Although BCG virulence and host im-
munocompetence play a role, trauma to the lower uri-
nary tract is the most common predisposing factor
(Lammet al. 1992). This is reflected in the list of contra-
indications to intravesical BCG therapy, which include
traumatic catheterization and gross or microscopic he-
maturia (Table 13.2) (Malkowicz 2002; Lamm et al.
1992). While the literature is sparse, small series have
demonstrated no significant morbidity with the use of
intravesical BCG in renal transplant patients (Palou et
al. 2003). Apart from a lower rate of fever with the Pa-
steur strain, the relative rates of fever, BCG-osis and
Table 13.2. Contraindications to intravesical BCG therapy
Absolute Relative
Traumatic catheterization Microscopic hematuria
Gross hematuria Poor performance status
Immunocompromised Advanced age
Acquired immunodefi-
ciency syndrome
Prior history of tuberculosis
Seropositive human im-
munodeficiency virus
Leukemia
Hodgkin’s disease
Transplant recipients
Prior BCG sepsis
Prior BCG-osis (pulmonary,
hepatic)
Intractable urinary tract
infection
Pregnancy
Lactation
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BCG sepsis among the five commercially available
strains of BCG are quite similar (Lamm et al. 1992). Pri-
or febrile responses to BCG therapy and positive skin
reactivity to purified protein derivative have both been
shown to be predictive of an increased risk of fever and
a trend toward an increased risk of systemic side effects
(Lamm 1992; Bilen et al. 2003). Interestingly, patients
who develop systemic side effects to BCG demonstrate
longer disease-free and progression-free survival from
an oncologic standpoint (Bilen et al. 2003; Suzuki et al.
2002). This implies that patients who mount an aug-
mented systemic reaction toward BCG may also mount
a more effective inflammatory response against the
bladder tumor.
13.4.1
BCG-Related Fever
Low-grade fever (<38.5°C) in the absence of hemody-
namic instability is a benign immune response to my-
cobacterial exposure in most cases. Outpatient symp-
tomatic treatment with oral antipyretics is typically all
that is necessary. Resolution should be expected within
24–48 h of treatment (Rischmann et al. 2000). High-
grade fever (>39.5°C), which develops in 3%–4% of
patients, or persistent low-grade fever are more worri-
some (Lamm et al. 1992; Resel Folkersma et al. 1999).
Current recommendations are to evaluate all patients
with fevers above 38.5°C or 39.5°C lasting longer than 24
or 12 h, respectively, and to initiate single-agent antitu-
bercular treatment on an empiric basis (Malkowicz
2002). The evaluation of BCG-related fever includes a
CBC as well as serum electrolytes, creatinine, liver
function studies, and mycobacterial blood cultures.
Gram-negative sepsis is not an uncommon cause of fe-
ver in this patient population; therefore standard blood
and urine cultures should also be obtained in order to
rule out infection by common urinary pathogens. Re-
spiratory symptoms suspicious for pulmonary infec-
tion warrant a plain radiograph of the chest. Isoniazid
(INH) (300mg once a day bymouth) is the antitubercu-
lar agent of choice for BCG-related fever. The most
common adverse effect of INH is transient hepatitis
manifest as elevated serum transaminase levels. This
occurs in 10%–20% of patients and should normalize
despite the continuation of treatment (Lamm et al.
1992). Isoniazid is continued for 3months and need on-
ly be discontinued if transaminases rise above three
times the upper limit of normal. Prophylactic INH has
not been shown to reduce the incidence of fever or sys-
temic infection (Durek et al. 2000). Moreover, prophy-
lactic INH diminishes the immune response and im-
pairs antitumor activity (de Boer et al. 1992).
13.4.2
BCG Sepsis
The most serious complication of BCG therapy is gen-
eralized sepsis secondary to intravascular absorption
ofmycobacteria or other urinary pathogens. Traumatic
catheterization, identified in more than two-thirds of
such cases, is themost common etiologic factor (Lamm
1992). Severe cystitis and recent transurethral surgery
(within 1 week) are other potential routes for dissemi-
nation. Fever is the most common presenting sign and
typically occurs within 12 h of BCG instillation (Pater-
son and Patel 1998). High-grade fever within 2 h of BCG
instillation is especially worrisome, as is hemodynamic
instability and other signs of multisystem organ failure
(Dalbagni and O’Donnell 2006). Blood and urine cul-
tures are typically negative. The mortality rate of BCG
sepsis approaches 50%; therefore empiric triple-drug
therapy is indicated in any patient with persistent fever
and evidence of sepsis in temporal association with
BCG administration (Malkowicz 2002; Paterson and
Patel 1998). A 6-month course of INH, rifampin, and
ethambutol is the current standard of care (Table 13.3).
Ethambutol may be discontinued after 2 months de-
pending upon organism susceptibility and clinical res-
olution (Blumberg et al. 2003). Since the treatment re-
sponse to antitubercular medications is delayed by
2–7 days, traditional guidelines recommended concur-
rent therapy with cycloserine, an antibiotic capable of
controlling mycobacteria within 24 h (Lamm et al.
1992; Lotte et al. 1984). Recent susceptibility studies,
however, have demonstrated that commercially avail-
able BCG strains are highly resistant to cycloserine. In
contrast, fluoroquinolones, gentamicin, and all antitu-
bercular drugs, except pyrazinamide, retain activity
against BCG (Durek et al. 2000). As such, contemporary
guidelines recommend the addition of a fluoroquinolo-
ne or ampicillin plus gentamicin combination to stan-
dard antitubercular therapy in cases of BCG sepsis (Du-
rek et al. 2000; Paterson and Patel 1998). This allows
rapid inhibition of mycobacterial growth while also
providing adequate empiric coverage for possible
Gram-negative sepsis. The duration of treatment with
supplementary antibiotics, determined by the results of
Table 13.3. Treatment of BCG sepsis
Medication Dosage Duration
Isoniazid plus 300 mg p.o. daily 6 Months
Rifampin plus 600 mg p.o. daily 6 Months
Ethambutol plus 1,200 mg p.o. daily 2–6 Months
Ampicillin plus
Gentamicina
1 g i.v. every 6 h Await culture
results7 mg/kg i.v. every 24 h
Or ciprofloxacin 500 mg p.o. twice daily
or 400 mg i.v. every 12 h
a Based on potential nephrotoxicity, gentamicin dosing re-
quires assessment of renal function
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standard blood and urine cultures, need only be short-
term in true BCG sepsis. One caveat is the development
of intolerance or systemic complication to any of the
standard antitubercular drugs, in which case a fluoro-
quinolone may be used in substitution.
The use of corticosteroids in BCG sepsis is some-
what controversial. Severe type IV hypersensitivity is
an important diagnosis to consider in any patient with
suspected BCG sepsis. Since the two diagnoses are of-
ten difficult to differentiate, most authorities recom-
mend the addition of corticosteroids (prednisolone
40 mg p.o. daily) or hydrocortisone 100 mg i.v. four
times daily (Lamm 1992; Paterson and Patel 1998) to
standard treatment in the short term. Animal studies
have shown that prednisolone in combination with
standard antitubercular therapy is more effective than
standard therapy alone (DeHaven et al. 1992). Exacer-
bation of true BCG sepsis secondary to immunosup-
pression remains a concern; therefore the decision to
continue steroid therapy should be made relatively
soon, based on clinical and laboratory parameters.
13.4.3
BCG-osis
BCG-osis is a variant of systemic infection wherein the
lungs, liver, or both are primarily affected (Malkowicz
2002). The clinical picture is similar to that of BCG sep-
sis; however, patients with BCG-osis are generally he-
modynamically stable and present with signs and
symptoms indicating pulmonary or hepatic disease.
Although an abnormal chest radiograph or elevated
liver enzymes suggest the diagnosis, only bronchoalve-
olar aspiration or biopsy of the lungs or liver are con-
clusive (Rischmann et al. 2000). Not uncommonly,
these biopsies are negative, indicating that many such
cases represent a hypersensitivity reaction rather than
a true mycobacterial infection. Regardless, a 6-month
course of INH and rifampin is indicated if clinical sus-
picion is high (refer to Table 13.3) (Lamm et al. 1992).
Ethambutol is added if the patient is acutely ill, as are
corticosteroids in cases unresponsive to standard treat-
ment. A prior history of BCG sepsis or BCG-osis pre-
cludes future treatment with intravesical BCG.
13.5
Malignant Spinal Cord Compression
Spinal cord compression is a debilitating complication
of metastatic cancer identified in 5%–14% of cancer
patients (Patchell et al. 2005). Among urologic malig-
nancies, it is most commonly seen with prostate cancer
(PCa), which accounts for 9%–24% of cases overall
(van der Linden et al. 2005; Flynn and Shipley 1991). In
fact, PCa is the second most common cause of malig-
nant spinal cord compression, with a cumulative inci-
dence of 7% (Manglani et al. 2000; Rosenthal et al.
1992; Sorenson et al. 1990). Although RCC and TCC ac-
count for 6% and 2% of cases, respectively, PCa, by vir-
tue of its higher incidence and preponderance for ver-
tebral metastases, warrants the bulk of discussion.
However, despite a few minor variances, the treatment
principles are the same regardless of malignant etiolo-
gy.
Prostate cancer is the most commonly diagnosed
noncutaneous malignancy in Americanmen today and
the second most common cause of cancer death (Jemal
et al. 2005). Screening through the use of serum pros-
tate-specific antigen (PSA) has led to both stage and
riskmigration such that the proportion of patients pre-
senting with metastatic disease has fallen from 14.1%
in 1988 to 3.3% in 1998 (Paquette et al. 2002). While
distant metastatic disease is now uncommon at presen-
tation, an additional 70% of patients with locally ad-
vanced PCa can be expected to develop metastases in
follow-up (Coleman 1997). Skeletal metastases are the
most common form of extralymphatic disease, and
based on venous drainage patterns the bony pelvis and
spine often represent the first sites involved.
In addition to significant pain and the potential for
pathologic fracture, metastases to the vertebral column
may cause spinal cord compression through local
growth into the epidural space (Byrne 1992). Direct
compression of the spinal cord causes edema, venous
congestion, and demyelination, all of which impair
neurologic function (Patchell et al. 2005). Prolonged
compression eventually leads to infarction of the spinal
cord. Without prompt diagnosis and treatment, pro-
gressive and irreversible loss of neurologic function
will occur. All too often, however, presentation and di-
agnosis are delayed.
13.5.1
Presentation
Midline back pain is the most common presenting
symptom (90%) (Gilbert et al. 1978; Sundaresan et al.
1985; Harrington 1988; Maranzano and Latini 1995). It
is typically localized to the level of cord compression
and, unlike degenerative disc disease, it is exacerbated
by recumbency and improved by upright posture
(Dodge et al. 1951). Radicular pain secondary to nerve
root compression is less frequent but highly localizing.
Symptom progression is usually slow with pain predat-
ing further neurologic changes by a median of 7 weeks
(Quinn and DeAngelis 2000). Progression of neurolog-
ic dysfunction can, on occasion, take place over a mat-
ter of hours or days; therefore, new onset back pain in a
cancer patient requires urgent evaluation.
Motor weakness is the secondmost common feature
of cord compression. As a result of delays in both pre-
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sentation and diagnosis, more than three-quarters of
patients present with objective motor deficits (Gilbert
et al. 1978; Harrington 1988). Regardless of the com-
pression site, weakness begins in the legs and affects
proximal muscle groups first (Quinn and DeAngelis
2000). Progression to paraplegia is typically a late
event. Sensory changes are also common (50%) and
occur soon after the onset of muscle weakness (Tazi et
al. 2003). Symptoms include hyperesthesia at the level
of compression or paresthesias and sensory loss in the
toes with proximal ascent. Urinary retention, fecal in-
continence, and impotence are usually late signs indi-
cating autonomic dysfunction. An exception is cauda
equina syndrome in which lumbar metastases cause
compression of the conus medullaris. Autonomic dys-
function can occur early in this setting and sensory loss
often assumes a saddle-like distribution.
13.5.2
Evaluation
Any cancer patient with new-onset back pain or neuro-
logic change requires a thorough evaluation to rule out
cord compression. A meticulous neurologic exam is
performed to determine the initial spinal level and se-
verity of compression. Interval changes are document-
ed through periodic repeat examinations. A normal
neurologic exam does not exclude the presence of im-
pending cord compression. Up to 36% of patients with
back pain and no neurologic deficits will have epidural
metastases demonstrated on imaging (Rodichok et al.
1981).MRI is the imagingmodality of choice in cases of
suspected spinal cord compression (Fig. 13.3) (Mangla-
ni et al. 2000; Quinn and DeAngelis 2000). While plain
radiography allows a quick assessment of vertebral col-
lapse and deformity, MRI provides an accurate deter-
mination of both the degree of compression and the
number of cord levels affected. A total of 10%–38% of
cases involve multiple noncontiguous levels; therefore,
the entire spine must be imaged (Byrne 1992; Helweg-
Larsen et al. 1995). The thoracic spine is the most com-
mon site of cord compression, and accounts for approx-
imately two-thirds of cases involving PCa (Flynn and
Shipley 1991). CT with or without myelography may be
used in cases where MRI is contraindicated or unavail-
able. SerumPSA and testosterone levels should bemea-
sured in cases of PCa to determine the androgen sensi-
tivity of the malignancy.
13.5.3
Treatment
As a late manifestation of advanced disease, the treat-
ment of malignant spinal cord compression is pallia-
tive. The primary objectives are pain relief and neuro-
logic preservation while reduction of tumor bulk re-
Fig. 13.3. Spinal cord compression. MRI demonstrating neo-
plastic replacement of L3 and L4 vertebrae and epidural com-
pression of spinal cord in patient with metastatic prostate can-
cer
mains a secondary goal only. Available treatment op-
tions include medical, radiation, and surgical thera-
pies, which are typically delivered in a multidisciplin-
ary fashion. Historically, intravenous corticosteroids in
combination with external beam radiotherapy (EBRT)
were the treatment of choice. Recent advances in spinal
instrumentation and surgical techniques have led to a
renewed interest in the use of surgery as primary thera-
py. Since there are no large-scale studies of urologic or
PCa-related spinal cord compression, current guide-
lines are based upon the results of studies incorporat-
ing numerous tumor types. Although oncologic prog-
nosis, presence of co-morbidities, and overall perfor-
mance status are important, ambulatory status and spi-
nal stability at presentation are the primary consider-
ations when formulating a treatment plan. Numerous
studies have demonstrated the prognostic significance
of baseline ambulatory status with regard to treatment
outcome. The majority of ambulatory patients can ex-
pect to remain ambulatory with early treatment,
whereas only 50% of nonambulatory patients, at best,
can expect the same (Ok et al. 2005).
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Table 13.4. Steroid protocols for malignant spinal cord com-
pression
Dexamethasone Bolus Maintenance
High dose 100 mg i.v. 24mg i.v./p.o. every 6 hs
for 3 days then taper
Moderate dose 10 mg i.v. 4 mg p.o./i.v. every 6 h
for 3 days then taper
Regardless of ambulatory status and spinal stability,
corticosteroids are the first treatment administered in
cases of suspected or confirmed spinal cord compres-
sion. Through a rapid reduction in vasogenic edema,
corticosteroids decrease mechanical compression on
the spinal cord until more definitive therapy can be
provided. Additional steroid actions include pain re-
lief, reduction in inflammation, and a direct oncolytic
effect (Ok et al. 2005). Corticosteroids can be given in
both high-dose and moderate-dose schedules (Ta-
ble 13.4) (Manglani et al. 2000). The two dosing sched-
ules appear to provide similar rates of neurologic and
ambulatory preservation; however, high-dose cortico-
steroids are associated with superior analgesia at the
expense of a greater risk of steroid-related complica-
tions (gastroduodenal ulceration, psychosis, Pneumo-
cystis carinii pneumonia) (Heimdal et al. 1992; Delattre
et al. 1988). Since no randomized controlled trials have
directly compared these two schedules, it is difficult to
make firm recommendations for steroid dosing. To
minimize the potential for steroid-related morbidity, it
has been suggested that corticosteroid therapy begin
with the moderate dose schedule. If neurologic im-
provement does not occur within 6–12 h, the high-
dose schedule can be implemented at that time (Mang-
lani et al. 2000). Maintenance dosing is continued until
the neurologic status remains stable for 48 h, after
which steroids are tapered over 2–3 weeks.
Androgen deprivation therapy maintains an impor-
tant role in the treatment of metastatic spinal cord
compression involving hormonally naı¨ve PCa. Unfor-
tunately, most patients with PCa who develop spinal
cord compression have exhausted hormonal therapy
and are resistant to such therapy. Nevertheless, all PCa
patients require an evaluation of serumPSA and testos-
terone to determine the level of androgen sensitivity
that remains. Hormonally naı¨ve cases demonstrate im-
proved ambulatory rates (80% vs 42%) and overall sur-
vival (16 vs 6 months) relative to hormone-resistant
cases when androgen deprivation is incorporated into
the overall management plan (Iacovou et al. 1985;
Flynn and Shipley 1991). Methods available for hor-
monal therapy include both surgical (bilateral orchiec-
tomy) and chemical (ketoconazole) castration. Or-
chiectomy and ketoconazole allow the most immediate
reduction in serum testosterone levels. Ketoconazole,
an oral synthetic imidazole antifungal agent, reduces
gonadal and adrenal testosterone synthesis through the
inhibition of cytochrome P450 enzyme-dependent 14-
demethylation of lanosterol to cholesterol. At a dose of
400 mg three times daily, ketoconazole suppresses se-
rum testosterone to castrate levels within 48 h (Trach-
tenberg 1984). Prostate cancer-related spinal cord com-
pression with neurologic compromise is a relative con-
traindication to the use of luteinizing hormone-releas-
ing hormone (LHRH) agonists. These agents induce a
temporary rise in serum testosterone, termed the flare
phenomenon, which begins within 2–3 days and lasts
approximately 1 week from the initiation of therapy
(Bubley 2001). Such a rise in serum testosterone may
lead to symptomatic disease progression, which, in the
context of documented spinal cord compression, can
involve a further deterioration in neurologic function.
Patients in whom spinal cord compression is impend-
ing rather than provenmay be candidates for LHRHag-
onist therapy; however, pretreatment with a steroidal
or nonsteroidal antiandrogen is recommended. Anti-
androgen therapy is preferably begun 1week before the
initiation of LHRH agonist treatment and continued
for 1 month. Luteinizing hormone-releasing hormone
antagonists, such as abarelix, represent an acceptable
alternative to LHRH agonists since they rapidly achieve
castrate serum testosterone levels (68%–78% within
7 days, 96%within 1month) and avoid the testosterone
surge altogether (Trachtenberg et al. 2002; Koch et al.
2003). Abarelix has demonstrated safe and effective
provision of medical castration in men with symptom-
atic PCa, including those with impending spinal cord
compression (Koch et al. 2003).
Ambulatory patients with spinal stability are usually
managed nonoperatively. For this group, the gold stan-
dard treatment is corticosteroids in combination with
EBRT. Radiotherapy is begun soon after the initiation of
corticosteroids with dosages of 2,000–4,000 cGy admin-
istered over a 2- to 4-week period (Manglani et al. 2000).
For optimal results, the radiation portal includes a mar-
gin of one or two vertebral bodies above and below the
site of compression (Quinn andDeAngelis 2000). Radio-
therapy decreases cord compression through a reduc-
tion in tumor mass and bone turgor. Paradoxically, this
may lead to weakening of the vertebral body and sub-
sequent collapse; therefore, patients often require
6–10 weeks of external bracing while bone healing takes
place. Preservation of ambulation can be expected in
70%–100%of patients treated in thismanner (Sundare-
san et al. 1985;Maranzano and Latini 1995; Katagiri et al.
1998; Helweg-Larsen 1996; Tomita et al. 1983). Radio-
therapy and corticosteroids together are more effective
than EBRT alone with ambulatory rates of 81% and
61%, respectively, demonstrated in a randomized con-
trolled trial (Sundaresan et al. 1985).
Nonambulatory, nonparaplegic patients with stable
spines are more difficult to manage. Significant motor
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deficit is a sign of severe and longstanding spinal cord
compression and only a minority of treated patients
can be expected to regain the ability to walk. Cortico-
steroids plus EBRT provide post-treatment ambulatory
rates of 6%–60% and likely favor the lower end of this
spectrum (Maranzano and Latini 1995; Tomita et al.
1983; Turner et al. 1993; Sorensen et al. 1994; Leviov et
al. 1993). Based on a clear inferiority to EBRT and a lack
of proven benefit in combination with EBRT, surgery
has not had a prominent role in this subgroup. Howev-
er, this practice was based upon the results of decom-
pressive laminectomy, a historical procedure with infe-
rior outcomes. Although most vertebral metastases are
located anterior to the spinal cord, laminectomy typi-
cally removes only posterior elements and does not re-
move the bulk of the compressive tumor. Furthermore,
laminectomy may actually destabilize the spine, there-
by worsening postoperative ambulatory rates. Over the
past two decades, vertebrectomy and spinal stabiliza-
tion have gained popularity based on the successful re-
sults of several nonrandomized studies (Siegel et al.
1982, 1985; Harrington 1984; Sundaresan et al. 1984;
Overby and Rothman 1985; Klimo et al. 2005). This
procedure, which takes an anterior approach, seeks to
decompress the spinal cord through the resection of all
gross disease. Concurrent spinal instrumentation pro-
vides immediate spinal stabilization even in cases of
near-total vertebral body excision.
A recent randomized trial comparing vertebrectomy
plus spinal stabilization in combination with EBRT vs
EBRT alone has confirmed the utility of primary sur-
gery in cases of metastatic spinal cord compression
(Patchell et al. 2005). Postoperative ambulatory rates
(84% vs 57% overall) and duration of ambulation (me-
dian, 122 days vs 13 days) were both superior with di-
rect decompressive surgery, regardless of baseline am-
bulatory status. In fact, 62%of nonambulatory patients
regained the ability to walk after surgery compared to
19% with radiation alone. Although this study did not
include patients with paraplegia persisting longer than
48 h, older series suggest that immediate surgery is also
advantageous in this group (Barcena et al. 1984). Un-
fortunately, only a minority of paraplegic patients
(<30%) can expect to regain ambulation with such
treatment. The superior functional results of surgery
likely reflect the provision of immediate decompres-
sion before irreversible spinal infarction takes place as
well as the removal ofmaximal tumor bulk, whichmin-
imizes the possibility of malignant regrowth and sec-
ondary compression. Of importance, no excess mor-
bidity ormortality could be ascribed to surgery and the
mean duration of hospitalization was only 10 days in
both groups. Although this randomized study demon-
strated a superior functional outcome with surgery for
both ambulatory and nonambulatory patients, verte-
brectomy and spinal stabilization is not yet considered
Table 13.5. Indications for surgical management of spinal cord
compression secondary to prostate cancer metastases
Surgical indications
Spinal instability or vertebral body collapse
Nonambulatory patients who fail to respond to radiotherapy
Progressive neurologic deterioration during radiotherapy
Bone extending into spinal canal causing thecal compression
Radiculopathy with progressive or uncontrolled symptoms
Spinal cord compression in a previously irradiated area
Paraplegic or severely paraparetic patients with recent neu-
rologic deterioration
a panacea. Commonly accepted indications for surgical
decompression are outlined in Table 13.5 (Baehring
2005).
13.6
Neutropenia
Neutropenia, defined as an absolute neutrophil count
of less than 500 cells/µl, occurs frequently in cancer pa-
tients undergoing systemic chemotherapy. Among pa-
tients with genitourinary malignancies, this scenario is
most common in patients with advanced TCC of the
bladder. In this setting, the administration of MVAC
(methotrexate, vinblastine, doxorubicin, cisplatin) or
GC (gemcitabine, cisplatin) chemotherapy leads to the
development of grade 3 or 4 neutropenia (WorldHealth
Organization classification) in 80% and 43%–71% of
patients, respectively (von der Masse et al. 2000). Al-
though less frequent, neutropenia may also occur with
conventional (bleomycin, etoposide, cisplatin) and sal-
vage (ifosfamide-based) chemotherapy during the
treatment of metastatic germ cell cancer (Bosl et al.
2005).
Neutrophils represent the first cellular component of
the inflammatory response. As such, neutropenia poses
significant risk for the development of infection. Both
the degree and duration of neutropenia have been
shown to correlate strongly with the incidence of seri-
ous infection (Bodey et al. 1966). Numerous risk factors
have been identified for the development of neutrope-
nia and subsequent infection. Patient-specific risk fac-
tors include hematologic malignancy, advanced tumor
stage, significant co-morbidities, poor performance
status, and advanced age, while treatment-specific risk
factors include chemotherapy type and dose intensity
(Crawford et al. 2004). Incorporation of these risk fac-
tors into predictive models serves to guide prophylaxis
and treatment recommendations against neutropenia
(Lyman et al. 2005).
The inflammatory response to infection is severely
weakened in the setting of neutropenia. Not only does
this predispose to the development and rapid progres-
sion of infection, but it also lessens the associated signs
and symptoms thereof. To prevent the development of
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infection and infection-related complications, it is es-
sential that neutropenic cancer patients receive prompt
evaluation and appropriate management. Antimicrobi-
al prophylaxis for the prevention of infection is contro-
versial. While clinicians are divided on its use, current
guidelines recommend against the use of prophylactic
antibiotics in neutropenic patients without fever, citing
a lack of consistent reduction in mortality rates as well
as concern over the emergence and propagation of
drug-resistant bacteria and fungi (Hughes et al. 2002).
An exception to this rule is found in patients consid-
ered to be at high risk for the development of Pneumo-
cystis carinii pneumonitis. In these patients, prophy-
lactic trimethoprim-sulfamethoxazole is recommend-
ed. Hematopoietic growth factors such as granulocyte
colony-stimulating factor (filgrastim) or granulocyte-
macrophage colony-stimulating factor (sargramostim)
represent additional potential treatment options.
When given as primary prophylaxis, these agents can
reduce the incidence of febrile neutropenia by as much
as 50% (Ozer et al. 2000). However, the American Soci-
ety of Clinical Oncology (ASCO) does not recommend
the routine use of prophylactic colony-stimulating fac-
tors in patients undergoing chemotherapy since no im-
provements in survival or response rate have been
demonstrated with such practice (Ozer et al. 2000).
Likewise, therapeutic colony-stimulating factor is not
recommended as routine treatment for afebrile neutro-
penic patients based on a demonstrated lack of clinical
benefit. Finally, adjustments to the chemotherapy regi-
men may become necessary in some neutropenic pa-
tients. Although this allows for bone marrow recovery,
it should be considered an option of last resort since
lower cancer-specific survival is well documented
among patients receiving less than full-dose chemo-
therapy (Lepage et al. 1993; Budman et al. 1998).
13.6.1
Febrile Neutropenia
Febrile neutropenia is defined as: (1) a single oral tem-
perature above 38.3°C or a temperature of 38.0°C or
higher lasting longer than 1 h, and (2) an absolute neu-
trophil count below 500 cells/µl (Hughes et al. 2002). Of
bladder cancer patients undergoing CMV or MVAC
chemotherapy regimens, 10%–14% meet these estab-
lished criteria (Gilligan et al. 2003). The importance of
febrile neutropenia lies in the fact that infection is the
most common cause of fever in the neutropenic setting
(50%) and, in turn, the leading cause of chemotherapy-
related death (Schimpff 1986). As such, fever in the con-
text of neutropenia is considered to reflect active infec-
tion until proven otherwise.
13.6.1.1
Evaluation
Patients that meet the criteria for febrile neutropenia
require urgent evaluation. The purpose of initial evalu-
ation is twofold: (1) assess for the presence and site of
infection and (2) determine the risk of significant in-
fection-related complications. Evaluation begins with a
thorough history and meticulous physical examina-
tion. Among immunocompromised patients, the clas-
sic signs and symptoms of infection are unreliable. A
complete head-to-toe examination should be under-
taken wherein every minor finding suspicious as a site
or route of infection is investigated further. The gastro-
intestinal tract, lungs, skin, mouth, and pharynx de-
serve special consideration since endogenous flora
originating from these sites account for the majority of
neutropenic infections (Marchetti and Calandra 2004;
Crawford et al. 2004). Careful evaluation of surgical
scars, biopsy sites and venous catheter sites, if present,
should also be made. The perineum and perianal re-
gion are often overlooked sites of infection that require
careful inspection and palpation.
The initial laboratory evaluation includes a CBC and
differential, electrolytes, BUN, creatinine, liver func-
tion studies, as well as cultures of blood (two sites) and
urine. Sputum, cerebral spinal fluid, skin lesions, and
stool should also be cultured if there is clinical suspi-
cion of infection involving these sites. Most recom-
mend obtaining a plain chest radiograph in all patients
regardless of clinical findings. Ambulatory patients
without clinical signs of pulmonary infection do not
routinely require imaging of the chest because it is of-
ten of low diagnostic yield (Oude Nijhuis 2003; Sipsas
et al. 2005). Laboratory and radiologic examinations
may be insensitivemarkers of infection in the setting of
neutropenia. As an example, up to 89% of febrile neu-
tropenic patients with urinary tract infection lack py-
uria and 40% of patients with pneumonia will have no
abnormal findings on chest radiography.
13.6.1.2
Treatment
Empiric antibiotic therapy forms the cornerstone of
treatment for febrile neutropenia and should be started
immediately upon diagnosis. With such treatment, re-
ductions in infection-related mortality have been ob-
served over the past three decades. However, a mortali-
ty rate of 8% among contemporary hospitalized cancer
patients with febrile neutropenia would seem to indi-
cate that this condition remains a serious threat to life
(Crawford et al. 2004). It has become clear that patients
with febrile neutropenia are not all alike, and treatment
regimens may be individualized. The Infectious Dis-
eases Society of America (IDSA) has published guide-
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Table 13.6. Infectious Diseases Society of America (IDSA) rec-
ommended antibiotic regimens for empiric treatment of fe-
brile neutropenia
Setting Regimen
Low risk Ciprofloxacin plus amoxicillin-clavulanate
High risk
Monotherapy Cefepime or
Ceftazidime or
Imipenem or
Meropenem
Combination Aminoglycoside plus
Antipseudomonal penicillin or
Cephalosporin (cefepime or ceftazidi-
me) or
Carbapenem
Combination
with vanco-
mycin
Cefepime or ceftazidime ± aminoglycoside
or
Carbapenem ± aminoglycoside or
Antipseudomonal penicillin + aminoglyco-
side
lines to facilitate the treatment of cancer patients with
neutropenic fever (Table 13.6) (Hughes et al. 2002). A
complete review of this complex topic is beyond the
scope of this chapter; however, the treatment principles
deserve discussion.
The IDSA treatment guidelines are based upon an
individualized assessment of risk as determined by
prognostic models. One such model, the Multinational
Association of Supportive Care in Cancer (MASCC)
Scoring Index, accurately predicts the risk of infection-
related complications in neutropenic patients based
upon seven clinical variables each with independent
prognostic significance (Klastersky et al. 2000) (Ta-
ble 13.7). Patients are generally divided into two
groups: (1) low-risk (<5% risk of developing serious
infection-related complications) and (2) high-risk (all
other patients). Low-risk, compliant patients may be
treated on an outpatient basis with oral antibiotics, the
preferred agents being ciprofloxacin in combination
with amoxicillin-clavulanate. In contrast, high-risk pa-
tients require hospitalization for i.v. antibiotics and
close monitoring. The antibiotic of choice in high-risk
patients is controversial and depends upon patient,
cancer, and pathogen-related factors. Gram-negative
bacilli and Gram-positive cocci are the predominant
organisms involved and account for one-third and two-
thirds of all cases, respectively (Table 13.8) (Hughes et
al. 2002). Not only should the selected antibiotic regi-
men provide broad coverage of both groups, but it
should also reflect the prevalence and susceptibility
profiles of the individual institution. Historically, all
patients received aminoglycoside-containing combina-
tion antibiotic therapy. The results of numerous con-
temporary studies have found that empiric antibiotic
monotherapy provides similar efficacy to combination
therapy in cases of uncomplicated neutropenic fever,
Table 13.7.TheMultinational Association of Supportive Care in
Cancer (MASCC) Risk Scoring Index for identification of low-
risk febrile neutropenic patients at presentation
Characteristic Scorea
Extent of illnessb
No symptoms 5
Mild symptoms 5
Moderate symptoms 3
No hypotension 5
No chronic obstructive pulmonary disease 4
Solid tumor or no fungal infection 4
No dehydration 3
Outpatient at onset of fever 3
Age <60 yearsc 2
a Highest theoretical score is 26. A risk index score of & 21 indi-
cates that the patient is likely to be at low risk for complica-
tions and morbidity
b Choose one item only
c Does not apply to patients e 16 years of age
Table 13.8. Most common bacterial causes of febrile neutrope-
nia
Gram-positive cocci Gram-negative bacilli
Staphylococcus species Escherichia coli
Coagulase-positive (S. aureus) Klebsiella species
Coagulase-negative (S. epider-
midis and others)
Pseudomonas aeruginosa
Streptococcus species
S. pneumoniae
S. pyogenes
Viridans group
Enterococcus faecalis,E. faecium
Corynebacterium species
but with a lower rate of adverse reactions (De Pauw et
al. 1994; Furno et al. 2002). This has led to a paradigm
shift in treatment such that empiric antibiotic mono-
therapy is now considered appropriate for the majority
of patients. The IDSA currently recommends four anti-
biotics as appropriate empiric monotherapy: ceftazidi-
me, cefepime, imipenem, and meropenem (Hughes et
al. 2002). Piperacillin-tazobactam represents a fifth
monotherapy option with proven efficacy (Bow et al.
2003). Combination antibiotic therapy remains the
standard of care for low-risk cases treated with oral
therapy, high-risk cases involving hemodynamic insta-
bility, and cases arising from institutions with a high-
frequency of multidrug-resistant pathogens. Recom-
mended combination regimens include an aminogly-
coside with an antipseudomonal q -lactam or cephalo-
sporin (Table 13.6). The decision to add vancomycin is
based upon a presumed risk of Gram-positive infection
rather than routine practice. Indications for its empiric
use include (1) apparent catheter-related infection; (2)
positive blood culture for a Gram-positive bacterium;
(3) colonization withmethicillin-resistant Staphylococ-
cus aureus; and (4) hemodynamic instability without
an identifiable organism (Segal et al. 2005).
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The response to treatment is evaluated after
2–3 days of therapy. If the causative organism is identi-
fied, antibiotics may be tailored accordingly. Unfortu-
nately, the causative organism is confirmed in only
one-third of patients (Bodey et al. 1978). In the event
that the culture results are inconclusive, low-risk pa-
tients who remain afebrile and clinically stable may be
switched to, or continued on, oral ciprofloxacin plus
amoxicillin-clavulanate. Patients who demonstrate
persistent fever after 3–5 days of empiric therapy are at
risk for cryptic foci (e.g., abscess, endocarditis), resis-
tant organisms, as well as fungal or viral infections
(Sipsas et al. 2005). These patients require repeat evalu-
ation and, most likely, modification of empiric antibi-
otic therapy. This should be done in consultation with
an infectious disease specialist knowledgeable in the
care of cancer patients. The recommended duration of
antibiotic therapy for febrile neutropenia depends up-
on the absolute neutrophil count, presence or absence
of fever on day 3, culture results, clinical course, and
overall risk strata. The reader is referred to the 2002 ID-
SA guidelines in this regard (Hughes et al. 2002).
Antifungal therapy deserves appropriate consider-
ation in cases of persistent neutropenic fever. Fungal in-
fections account for 2%–10% of neutropenic infections
overall, and up to 30% of infections in patients with per-
sistent neutropenic fever (Wisplinghoff et al. 2003; de
Pauw et al. 1994). Furthermore, fungal septicemia car-
ries with it a high mortality rate, which approaches 90%
in certain subgroups of patients (Sipsas et al. 2005).
Based on the high prevalence and significant mortality
of fungal infections, the IDSA recommends the empiric
initiation of systemic antifungal therapy in neutropenic
patients with fever persisting 5 days despite appropriate
empiric antibiotic therapy (Hughes et al. 2002). Candida
and Aspergillus species constitute the most common
fungi identified. The drug of choice is amphotericin B,
although fluconazole is an acceptable alternative. In con-
trast, there is no indication for empiric antiviral therapy
in febrile neutropenic patients, nor are colony-stimulat-
ing factors routinely recommended. The use of antiviral
agents is generally limited to cases of documented viral
respiratory tract infection or documented herpes sim-
plex or varicella-zoster cutaneous infection. Cutaneous
viral infections, even if not the source of fever, require
treatment since they are potential portals of entry for
bacteria and fungi. Acyclovir, valacyclovir, or famciclo-
vir are all appropriate antiviral treatment options.
13.7
Intractable Bladder Hemorrhage
Gross hematuria is not uncommon among patients
with genitourinary malignancies. It can be the present-
ing sign of cancer involving the urinary tract or it may
arise as a direct complication of cancer treatment. In
most cases, the hematuria is of mild to moderate sever-
ity and resolves with conservative measures. Some
cases, however, involve intractable hemorrhage that
can be life-threatening without prompt and effective
treatment. Intractable gross hematuria usually arises
from the bladder secondary to advanced urothelial car-
cinoma, severe infection, chemotherapy-induced hem-
orrhagic cystitis, and radiation cystitis. Not only are
these disease processes the most common causes of se-
vere bladder hemorrhage, but they are also among the
most difficult to treat. The optimal management of in-
tractable bladder hemorrhage rests upon a determina-
tion of its cause and the institution of specific treat-
ment at that time. Commonalities do exist, however,
and they form the basis for management guidelines
with broad application to all patients with severe blad-
der hemorrhage.
13.7.1
Transitional Cell Carcinoma
Transitional cell carcinoma (TCC) of the bladder is the
fourth and ninth most common cancer in men and
women, respectively (Jemal et al. 2005). Gross or micro-
scopic hematuria is the typical manner of presentation
(>80%). Seventy-five percent of patients are found to
have superficial TCC while the remaining 25% are diag-
nosed with muscle-invasive disease. Treatment is pri-
marily surgical with transurethral resection and radical
cystectomy representing the standard options for super-
ficial and invasive TCC, respectively. Since hematuria
arises from the tumor itself, isolated or recurrent epi-
sodes of bleeding can be expected to resolve upon resec-
tion of the primary tumor. Exceptions do exist, however.
These include: (1) large or locally advanced tumors
deemed unresectable by cystectomy and (2) invasive tu-
mors diagnosed in patients whose health status pre-
cludes cystectomy. Transurethral resection alone is in-
adequate in these cases and patients often develop trou-
blesome hematuria as a consequence of inevitable tu-
mor progression. Patients with advanced bladder cancer
who fail conservative measures, as outlined below, may
receive benefit from the addition of external beam ra-
diotherapy. Radiotherapy for this purpose is generally
well tolerated and may lead to resolution of hematuria
in up to 59% of patients (Srinivasan et al. 1994).
13.7.2
Hemorrhagic Cystitis
Hemorrhagic cystitis is defined as gross hematuria sec-
ondary to diffuse inflammation of the bladder. Viral in-
fection, radiation-induced inflammation, and chemo-
therapy-induced inflammation account for the majori-
ty of cases among cancer patients. While relatively un-
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common in patients with genitourinary malignancies,
viral-mediated hemorrhagic cystitis occurs in as many
as 50%of patients undergoing bonemarrow transplan-
tation (Bedi et al. 1995). The principle etiologic factor
involved is the BK polyomavirus. Viral-mediated hem-
orrhagic cystitis often occurs several weeks after trans-
plantation and is usually self-limited. The role of anti-
viral therapy is unclear at present; therefore, no specific
treatment recommendations beyond standard hematu-
ria management can be made for viral hemorrhagic
cystitis.
The association between hemorrhagic cystitis and
the oxazaphosphorine alkylating agents, cyclophos-
phamide and ifosfamide, has been well documented
(Philips et al. 1961; Burkert 1983; Klastersky 2003).
These chemotherapeutic drugs are used frequently in
the treatment of breast cancer, lymphoma, and sarco-
ma but also have application in poor-risk and chemo-
therapy-resistant germ cell tumors. Cyclophosphamide
is associated with a 24% incidence of irritative voiding
symptoms, 7%–53% incidence of microscopic hema-
turia, and 1%–15% incidence of gross hematuria (Ta-
lar-Williams et al. 1996). Older series report hemor-
rhagic cystitis in as many as 68% of patients treated
with cyclophosphamide (Burkert 1983). The causative
agent of urothelial toxicity is acrolein, a hepatic metab-
olite eliminated primarily through urinary excretion
(Cox 1979). Peak urine levels occur approximately 5 h
after the start of chemotherapy infusion (Takamoto et
al. 2004). Early pathologic changes include transmural
edema, mucosal ulceration, and urothelial necrosis all
of which may occur within 24 h of a single dose (DeV-
ries and Freiha 1990). With repeated exposure, urothe-
lial damage is progressive andmay become irreversible
(Forni et al. 1964; Koss 1967). The entire urothelium is
at risk; however, the bladder is most frequently affected
as it receives the longest exposure. In the acute setting,
cystoscopy reveals diffuse inflammatory changes, while
in the delayed setting chronic changes such as edema,
pale mucosa, telangiectasia, and patchy inflammation
are prominent (Coleman and Walther 2005).
Contemporary studies report a lower incidence of
hemorrhagic cystitis secondary to cyclophosphamide
than do historical series. This is due in large part to the
development and routine application of preventative
measures such as hydration and prophylactic mesna
(sodium 2-mercaptoethane sulfonate). Intravenous
normal saline is given concurrently with cyclophos-
phamide infusion to reduce the urinary concentration
of acrolein through an increase in urine output (Philips
et al. 1961). Unfortunately, the prevention of clinically
significant urothelial damage is inconsistent with hy-
dration; therefore, hydration therapy alone cannot be
recommended as adequate prophylaxis. Mesna, a non-
toxic thiol compound, was specifically developed to
bind and inactivate acrolein without interfering with
tumor control (Brock et al. 1981). Numerous random-
ized trials have demonstrated the superiority of mesna
relative to placebo and hydration in the prevention of
gross hematuria (Araujo and Tessler 1983; Fukuoka et
al. 1991; Shepherd et al. 1991). With the routine incor-
poration of mesna into cyclophosphamide or ifosfami-
de-containing chemotherapy regimens, modern rates
of severe hematuria range from 0%–13%. Mesnamust
be administered before cyclophosphamide to ensure
adequate urinary levels are available when acrolein
reaches peak urinary concentration. For this reason,
mesna has no place in the treatment of established cy-
clophosphamide-induced hemorrhagic cystitis. Based
on simplicity, convenience, and proven efficacy, a two-
dosemesna regimen (15min before and 4 h after cyclo-
phosphamide) is recommended (Katz et al. 1995).
There is suggestion that the addition of dexamethasone
may improve the prophylactic efficacy ofmesna (Vieira
et al. 2003). Prior episodes of hemorrhagic cystitis do
not absolutely contraindicate the repeat administration
of cyclophosphamide or ifosfamide provided that mes-
na is given prophylactically (Andriole et al. 1987).
The management of cyclophosphamide-induced
hemorrhagic cystitis can be difficult. At the present
time, there is no specific therapeutic option that can be
recommended ahead of standard management strate-
gies. Intravesical prostaglandin (PGE1, PGE2, and
PGF2 [ ) therapy is one option that may hold future
promise. Initial interest in the use of prostaglandins
was generated by case reports of demonstrated success
in cases of otherwise intractable bladder hemorrhage
secondary to cyclophosphamide (Miller et al. 1994;
Trigg et al. 1990; Shurafa et al. 1987). Subsequent series
report 50% complete resolution of hematuria after the
administration of carboprost tromethamine (PGF2 [ )
for a median treatment period of 6 days (Levine and
Jarrard 1993). Although the exact mechanism of action
is unknown, prostaglandin may improve hematuria
through platelet aggregation and vasoconstriction.
Bladder spasms (78%) are a frequent occurrence with
intravesical prostaglandin therapy; however, adverse
effects on renal or bladder function are negligible as are
systemic complications. Prostaglandins have since
found application in the management of other forms of
severe hemorrhagic cystitis. Hyperbaric oxygen treat-
ment (HBO), typically reserved for cases of refractory
radiation cystitis, has also been used to treat hemor-
rhagic cystitis resulting from cyclophosphamide. Ani-
mal models suggest that HBO may be of value as pro-
phylaxis or treatment in this setting (Hader et al. 1993).
13.7.3
Radiation Cystitis
Radiation cystitis is a late complication of radiotherapy
which, by definition, occurs at least 90 days after the
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initiation of radiation treatment but may be delayed up
to 10 years or more (Cox et al. 1995). Most patients de-
velop severe irritative voiding symptoms; however,
gross hematuria dominates the clinical picture (Pas-
quier et al. 2004). While any patient receiving pelvic ra-
diotherapy is at risk, radiation cystitis is most common
among those treated for prostate or cervical cancer.
Three to five percent of such patients will develop late
grade 3 hematuria, the incidence of which is directly re-
lated to both the biologic dose and the volume of tissue
irradiated (Perez 1998; Lawton et al. 1991; Shipley et al.
1988; Dearnaley et al. 1999). In contrast to acute
changes, late radiation injuries are irreversible and of-
ten progressive. There appears to be no correlation be-
tween the development of early and late radiation inju-
ries. The pathophysiology of late radiation damage in-
cludes cellular depletion, fibrosis, and obliterative end-
arteritis (Pasquier et al. 2004). All of these changes lead
to tissue ischemia and, in turn, delayed wound healing.
Cystoscopically, such changes give the appearance of
pale, frosted mucosa, scattered telangiectasia, and ul-
cers (Rigaud et al. 2004).
Radiation cystitis is perhaps the most difficult form
of bladder hemorrhage to treat. The reason for this lies
primarily in the ischemic nature of the injury and the
propensity toward poorwound healing. Based on a lack
of randomized controlled trials comparing available
treatment options, firm guidelines for radiation cystitis
management cannot bemade (Denton et al. 2002). That
being said, a tremendous amount of research has been
devoted to examining the role of hyperbaric oxygen
therapy (HBO) in the treatment of radiation injuries.
First introduced into the field of radiation oncology in
1953 as a radiosensitizer, HBO has subsequently been
shown to ameliorate radiation damage among a wide
range of tissues, including the bladder (Gray et al. 1953;
Capelli-Schellpfeffer and Gerber 1999; Feldmeier and
Hampson 2002). Hyperbaric oxygen therapy involves
the inhalation of 100% oxygen pressurized to
1.4–3.0 atm in sessions of 60–120 min. Under these
conditions, alveolar, arterial, and tissue oxygen levels
are driven to supraphysiologic levels. By improving the
oxygenation of irradiated tissue, HBO stimulates an-
giogenesis, fibroblast proliferation, and collagen for-
mation (Marx et al. 1990). Not only does this promote
wound healing, but the vasoconstriction induced by an
abundance of oxygen may also help to control bleeding
(Capelli-Schellpfeffer and Gerber 1999). Retrospective
studies examining the role of HBO in severe radiation
cystitis report response rates of 77%–100% (complete
response, 34%–100%; partial response, 12%–45%)
(Mathews et al. 1999; Neheman et al. 2005). A single
prospective study of HBO demonstrated an overall re-
sponse rate of 92.5% among 40 patients with radiation
cystitis refractory to standard measures (Bevers et al.
1995). Patients underwent 20 treatment sessions inhal-
ing 100% oxygen at 3 atm for 90min each.With amean
follow-up of 23 months, the recurrence rate of severe
hematuria was 12% per year. It is difficult to predict the
individual treatment outcome; however, the provision
of HBO within 6 months of hematuria onset appears to
improve the response rate (96% vs 66%, p=0.003)
(Chong et al. 2005). Cancer patients who do not re-
spond to HBO require evaluation for cancer recurrence
since this is a common cause of persistent hematuria
(Rijkmans et al. 1989). Hyperbaric oxygen therapy is
generally well tolerated, with adverse events limited to
case reports of visual disturbance, spontaneous pneu-
mothorax, oxygen toxicity seizures, hypoglycemia, and
loss of respiratory drive in hypercapnic patients (Ca-
pelli-Schellpfeffer andGerber 1999). Contraindications
to the use of HBO are listed in Table 13.9 (O’Reilly et al.
2002). Concern exists over the theoretic risk of cancer
stimulation through HBO-mediated neoangiogenesis,
immune suppression, and free radical toxicity. A review
of the world literature in 2003, however, found that
available in vitro, in vivo, and clinical studies suggested
no more than a neutral effect of HBO on tumor growth
(Feldmeier et al. 2003). Additional studies have found
no evidence that exposure to hyperbaric oxygen pro-
motes tumor growth, including that of prostate cancer
(Chong et al. 2004). As such, a history of malignancy
should not be considered a contraindication to treat-
ment with HBO. Perhaps the largest obstacle to its use
is cost. The average cost per session is $ 300–$ 400,
which amounts to an estimated $ 10,000–$ 15,000 per
patient (Norkool et al. 1993). While there exist no for-
mal cost-comparisons among available treatments for
radiation cystitis, HBO is still regarded as a cost-effec-
tive option and should be considered for refractory
cases.
WF10, the i.v. formulation of a novel wound-healing
agent, tetrachlorodecaoxygen, has demonstrated bene-
fit in patients with wound healing disorders, including
that arising from radiation injury (Hinz et al. 1986; Vee-
rasarn et al. 2004). As an immune modifier, WF10 pro-
motes the healing process through the inhibition of the
chronic inflammatory process. Two human studies, in-
cluding one randomized trial have evaluated the effica-
Table 13.9. Contraindications to use of hyperbaric oxygen ther-
apy
Absolute contraindications Relative contraindications
Untreated pneumothorax Upper respiratory infections
Concurrent treatment with Seizure disorders
Cis-platinum High fevers
Doxorubicin History of spontaneous
pneumothoraxBleomycin
Viral infectionsDisulfiram
Congenital spherocytosisMafenide acetate
History of optic neuritis
History of otosclerosis
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cy of this novel agent in the treatment of radiation cys-
titis (Veerasarn et al. 2004, 2006). Among cervical can-
cer patients with grade 2 or 3 radiation cystitis, WF10
provided a complete response rate of 74%–88%. Al-
though this was not statistically superior to the stan-
dard hematuriameasures employed in the control arm,
patients treated with WF10 demonstrated a lower rate
of hematuria recurrence (47% vs 77%, p=0.01) and a
longer estimated time to recurrence (>300 days vs
<100 days, p=0.004). The administration protocols in
both studies involved 0.5 mg/kg WF10 in 250 ml nor-
mal saline infused over 2 h on 5 consecutive days every
3 weeks for two cycles. Transient hemoglobinemia may
occur in up to one-quarter of treated patients; however,
there have been no serious safety concerns with WF10
in these or any other studies to date. At this time, the
role of WF10 in the management of radiation cystitis
remains investigational.
13.7.4
Treatment of Intractable Bladder Hemorrhage
The approach to the patient with intractable bladder
hemorrhage is fairly standard and begins with a thor-
ough evaluation to determine its cause. Information
obtained on history (e.g., prior malignancy, prior ra-
diotherapy, prior cyclophosphamide, etc.) may suggest
the etiology; however, multiple factors may be involved
and assumptions should not be made. Outside of the
acute setting, all cases in which the etiology has not
been identified require a formal hematuria workup, in-
cluding cystoscopy, urine cytology, and upper tract im-
aging. The chronicity and severity of the hematuria as
well as any prior attempts at therapy are important to
determine. This may suggest to what degree, if any, the
hematuria is refractory to conservative measures. Pa-
tients with severe hematuria can develop urinary re-
tention secondary to the accumulation of blood clot
within the bladder; therefore, the ability to void should
be questioned. A list of the patient’s current medica-
tions should be reviewed and any anticoagulants dis-
continued accordingly. The primary goals of physical
examination are to determine the hemodynamic stabil-
ity and overall health status of the patient as well as the
presence of urinary retention. Laboratory studies
should include a CBC and differential, serum electro-
lytes, BUN, creatinine, coagulation profile, and urine
culture. Initial therapy is directed toward maintaining
hemodynamic support through i.v. fluids as well as
through blood and blood product replacement as nec-
essary.
Whatever the etiology, the management of gross he-
maturia follows the same general principles as outlined
in Table 13.10. Treatment is delivered in a stepwise
manner according to hemodynamic stability, hematu-
ria severity, and treatment response. A hematuria
Table 13.10. Graded management options for intractable blad-
der hemorrhage
Clot evacuation (catheter or cystoscopic) plus
Intermittent saline irrigation or
Continuous saline irrigation
Cystoscopy ± fulguration
Oral agents
E-aminocaproic acid (Amicar) (loading 5 g p.o./i.v., then
maintenance 1 g/h)a
Sodium pentosan polysulphate (Elmiron) (begin 100 mg
p.o. three times daily)
Intravesical agents
Alum 1% (250 ml/h via continuous bladder irrigation)b
Prostaglandin-E1, -E2, and -F2 [ (see text for dosing)
Formalin (begin e 4%, up to 10%)
Hyperbaric oxygen therapy
Embolization of internal iliac artery
Surgery (urinary diversion, with or without open bladder
packing or cystectomy)
a Maximum daily dose of Amicar is 30 g
b Do not exceed 3 g/h alum in patients with renal insufficiency
Table 13.11. Hematuria grading system and suggestedmanage-
ment
Grade Treatment
Mild
No acute decrease in hemat-
ocrit (Hct)
Saline irrigation
Oral Amicar or Elmiron
Intravesical alum
Moderate
Drop in Hct Above plus
Requires e 6 HU of packed
red blood cells to maintain
hemodynamic stability
Clot evacuation
Urinary clot retention
Cystoscopy ± fulguration
Intravesical prostaglandin or
formalin
Severe
Refractory to saline irriga-
tion, Amicar, alum, prosta-
glandin
Above plus:
Requires >6 HU of packed
red blood cells to maintain
hemodynamic stability
Intravesical formalin
Embolization
Surgery
grading system has been proposed to facilitate treat-
ment in this regard (Table 13.11) (DeVries and Freiha
1990). The first step involves bladder decompression
through the insertion of a large-bore urethral catheter
for clot evacuation and saline lavage. This is a simple
maneuver that may slow or stop the bleeding altogeth-
er. Continuous bladder irrigation (CBI) through a
three-way Foley catheter is initiated once the effluent is
clear or pink-tinged and free of clots. In some in-
stances, bedside lavage is inadequate and formal cysto-
scopic clot evacuation in the operating room becomes
necessary. During this time, the bladder is carefully in-
spected for a source of hemorrhage, and biopsies or ful-
guration of suspicious areas can be performed. Cases
not responsive to clot evacuation and fulguration or
those with cystoscopic evidence of diffuse hemorrhage
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require supplementary therapy with systemic or intra-
vesical agents.
E-aminocaproic acid (Amicar), given orally or par-
enterally, inhibits the process of fibrinolysis by prevent-
ing the activation of plasminogen to plasmin. It is used
commonly in the field of cardiothoracic surgery based
on demonstrated efficacy in the reduction of postoper-
ative hemorrhage (Trinh-Duc et al. 1992). Unfortunate-
ly, there have been no comparative trials evaluating the
efficacy of this agent in the context of hemorrhagic cys-
titis. Proponents of its use for bladder hemorrhage cite
anecdotal reports of apparent success in addition to the
evidence provided by disciplines outside of urology
(Aroney et al. 1980; Lakhani et al. 1999; Stefanini et al.
1990). Administration involves a loading dose of 5 g fol-
lowed by 1 g/h for 8 h or until bleeding stops. Themaxi-
mum recommended dosage in 24 h is 30 g. As an inhibi-
tor of fibrinolysis, E-aminocaproic acid promotes clot
formation; therefore, it should be used in conjunction
with CBI. Upper tract hemorrhage remains a contrain-
dication to its use since clot formationwithin the ureter
can lead to obstruction and acute renal failure.
Sodium pentosan polysulphate (Elmiron), given
orally, is a low-molecular-weight heparinoid that re-
places deficient glycosaminoglycans on the bladder
surface (Parsons et al. 2002). In doing so, it removes po-
tential triggers of hematuria by protecting the bladder
wall from bacterial adherence as well as from the ab-
sorption of toxic substances within the urine. Such pro-
tection may also facilitate healing of the bladder sur-
face. While used more commonly in the treatment of
interstitial cystitis, sodium pentosan polysulphate has
been shown to resolve hematuria in 50% of patients
with radiation or cyclophosphamide-induced hemor-
rhagic cystitis when given as first-line treatment (Par-
sons et al. 1993; Sandhu et al. 2004). Dosing begins at
100 mg three times daily with a gradual reduction to
100mg daily as hematuria improves. Treatment may be
discontinued when the hematuria resolves completely.
At this time, there is no data available regarding the rate
or time to recurrence with such therapy.
Of the commonly used intravesical agents, alum and
prostaglandins have the advantage of not requiring an
anesthetic. Alum (aluminium ammonium sulphate or
aluminium potassium sulphate) is an astringent that
causes protein precipitation, vasoconstriction, and de-
creased capillary permeability without damaging nor-
mal urothelium (Ostroff and Chenault 1982; Arrizaba-
laga et al. 1987). Commonly delivered as a 1% solution
(50 g alum in 5 l sterile water) via CBI at a rate of 250ml/
h, alum leads to the complete resolution of hematuria
in 60%–100% of hemorrhagic cystitis patients
(Ostroff and Chenault 1982; Gattegno et al. 1990;
Choong et al. 2000). The median time to resolution of
hematuria ranges from 3–4 days, but therapy may be
required for as long as 7 days. Up to 20%of patients will
develop recurrent hematuria within 5–10 months. The
risk of systemic toxicity is low because urothelial per-
meability to aluminum is minimal and prompt renal
excretion ensures elevated aluminum levels are avoid-
ed. There are case reports of aluminum encephalopathy
with intravesical alum, the majority of which occurred
in patients with baseline renal insufficiency (Kavoussi
et al. 1986; Shoskes et al. 1992; Perazella et al. 1993). In
addition to central nervous system disturbance (lethar-
gy, confusion, seizures), aluminum toxicity can result
in metabolic acidosis and coagulopathy. While renal
failure is not an absolute contraindication to the use of
intravesical alum, it should be used with caution and at
a dose that should not exceed 3 g/h (Kennedy et al.
1984). Aluminum levels should be monitored periodi-
cally in such patients. Intravesical alum irrigation
should be discontinued immediately if serum alumi-
num levels are elevated or systemic toxicity is suspect-
ed.
Prostaglandin-E1, -E2, and -F2 [ , already discussed
as a treatment option for cyclophosphamide-induced
hemorrhagic cystitis, may prove beneficial in cases
arising from a variety of other causes as well. Numer-
ous protocols for prostaglandin administration have
been described including: (1) 50ml of 4–10mg/l of car-
boprost tromethamine left indwelling for 2 h four times
per day alternating with saline CBI and (2) 8–10 mg/l
of PGF2 [ via saline CBI at a rate of 100 ml/h for 10 h
(Choong et al. 2000). Both protocols lead to a complete
response in 50% of patients treated over amedian peri-
od of 6 days (Levine and Jarrard 1993). A small trial
comparing intravesical PGF2 [ and 1%alum in patients
with hemorrhagic cystitis of unknown origin demon-
strated similar response rates of 80% and 90%, respec-
tively (Praveen et al. 1992). Although there was a com-
plete lack of systemic side effects in both groups, virtu-
ally all patients developed transient bladder spasms re-
quiring symptomatic control. Since prostaglandins are
very expensive, 1% alum remains the intravesical agent
of first choice.
The best known and most effective intravesical he-
mostatic agent is formalin, the aqueous solution of
formaldehyde. When administered intravesically, for-
malin rapidly fixes the bladder mucosa through a pro-
cess involving protein cross-linking. This prevents fur-
ther necrosis and blood loss from occurring (DeVries
and Freiha 1990). First introduced in 1969 for the treat-
ment of radiation cystitis, 10% formalin led to the com-
plete resolution of hematuria in 22 of 24 patients with
no serious side effects noted (Brown 1969). Since that
time, formalin has also demonstrated success in the
treatment of hemorrhagic cystitis. At the same time,
the potential for serious toxicity (up to 15%) with blad-
der formalinization is well documented. In light of the
potential for significant treatment-related morbidity,
formal instillation is generally reserved for cases of in-
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tractable bladder hemorrhage refractory to conserva-
tive treatment.
The results of a meta-analysis evaluating 235 cases of
intractable bladder hemorrhage treated with intravesical
formalin form the foundation upon which most recom-
mendations are made (Donahue and Frank 1989). For-
malin can be administered intravesically in concentra-
tions ranging from 1%–10% (typically 1%, 5%, 10%).
While there is a trend toward improved results with 10%
formalin, there is no statistical difference in complete re-
sponse among the three preparations (71%–83%). He-
maturia typically resolves within 48 h (1–5 days) and the
duration of response is 3–4 months, regardless of dose.
Major complications (5%–15%) include bladder con-
tracture, ureteral stenosis, acute renal failure, and even
death. Although there appears to be a trend toward a
higher rate of major complications with higher concen-
trations of formalin, this has never been proven. Similar-
ly, the rate ofminor complications (14%–78%), of which
irritative voiding symptoms aremost common, appear to
correlate with dose. Given the lack of comparative stud-
ies it is difficult to make firm recommendations regard-
ing the optimal concentration of formalin. There is some
suggestion that hematuria secondary to radiation cystitis
may require 5% or more formalin, while hematuria due
to cyclophosphamide or bladder cancer may require less
than 5% formalin; however, this is merely conjecture.
Most centers advocate the initial use of 4% or less forma-
lin since this concentration appears to optimize the treat-
ment response (>75%) while minimizing the potential
for minor and major complications (Russo 2000).
Formalin must be instilled under a spinal or gener-
al anesthetic since it is caustic to the sensory nerves of
the bladder. The procedure begins with a formal cys-
toscopic evaluation of the entire bladder and urethra.
Clot evacuation and fulguration of bleeding vessels
can be performed as necessary. Vesicoureteric reflux
significantly predisposes the patient to upper tract
damage with intravesical formalin; therefore a cysto-
gram must be performed prior to every instillation.
Documented reflux is not a contraindication to for-
malin treatment but does necessitate the insertion of
occlusive Fogarty balloon catheters into the affected
ureteric orifice(s) (Gottesman and Ehrlich 1974). Re-
verse Trendelenburg positioning and the induction of
a brisk diuresis can also protect against the reflux of
formalin. The presence of bladder perforation, which
remains an absolute contraindication to the use of for-
malin, can also be documented by a cystogram. Prior
to beginning formalin instillation, the entire perine-
um should be painted with petroleum jelly and, in
women, the vagina packed with petroleum jelly gauze
to protect exposed skin and mucosa from the caustic
effect of formalin. Through an 18-F Foley catheter, the
bladder is then filled to capacity with 1%–2% forma-
lin under gravity at a pressure kept below 15 cm H2O
(catheter level at 15 cm above pubic symphysis). Al-
though the optimal contact time is not known, most
recommend limiting the treatment session to 15 min
(Choong et al. 2000).
Approximately 10%–30% of patients with severe
hemorrhagic cystitis will not respond to low-dose for-
malin instillation. A second instillation using high-
dose formalin (5%–10%) remains an option; unfortu-
nately, repeat administration of formalin is associated
with a lower complete response rate (50%) and a higher
rate of major complications (40%). Treatment alterna-
tives include hyperbaric oxygen therapy, arteriograph-
ic embolization, and urinary diversion with or without
cystectomy. Hyperbaric oxygen is most appropriate for
refractory radiation cystitis as described above; howev-
er, animal studies suggest that it may also be of benefit
in cases of cyclophosphamide-induced hemorrhagic
cystitis (Hader et al. 1993).
Therapeutic embolization of the internal iliac artery
to control bladder hemorrhage was first reported in
1974 (Hald andMygind 1974). Most studies report a re-
sponse rate in excess of 80%, usually of immediate on-
set (McIvor et al. 1982; Rodriguez et al. 2003; Nabi et al.
2003). A common complication of embolization is se-
vere transient gluteal pain caused by claudication of the
superior gluteal artery (Choong et al. 2000). Case re-
ports of leg ischemia and bladder necrosis also exist
(Woodside et al. 1976; Braf and Koontz 1977). Improve-
ments in both technology and technique have led to su-
perselective embolization. With such procedures, the
efficacy of embolization is maintained while patient
morbidity is reduced (De Berardinis et al. 2005). Embo-
lization is most appropriate for those patients who are
refractory to conservative measures, including forma-
lin instillation, but whose health status precludes surgi-
cal intervention.
Open surgery is an option of last resort to be used
only in patients with massive intractable bladder hem-
orrhage who are otherwise good surgical candidates.
Open cystotomy combined with bladder packing and
percutaneous urinary diversion, cutaneous ureterosto-
my, and cystectomy with urinary diversion have all
been described, each with variable outcome (Andriole
et al. 1990; Pomer et al. 1983; Okaneya et al. 1993). Un-
fortunately, many patients with severe hemorrhagic
cystitis are elderly and unfit for invasive surgery. It is in
situations such as this that intractable bladder hemor-
rhage becomes a lethal event.
13.8
Ureteral Obstruction
Malignant ureteral obstruction is not rare among can-
cer patients, with a cumulative incidence of 4.4% in ad-
vanced cases (Coleman and Walther 2005). While pel-
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vic genitourinary malignancies such as ovarian, cervi-
cal, bladder, and prostate cancer (PCa) are the most
common causes of malignant ureteral obstruction
(70%), retroperitoneal lymphadenopathy secondary to
lymphoma, and germ cell cancer are not uncommon
(Holden et al. 1979). Obstruction may result from in-
tramural tumor growth, extramural compression, or
from retroperitoneal fibrosis secondary to cancer treat-
ment (Montana and Fowler 1989). Approximately 2.5%
of women who undergo definitive radiation treatment
for cervical cancer will develop ureteral obstruction
(McIntyre et al. 1995).
13.8.1
Presentation
Themanner of presentation of ureteral obstruction de-
pends upon the time course over which it develops and
whether or not both sides are involved. Acute unilateral
obstruction presents with the symptoms typical of re-
nal colic while chronic unilateral obstruction tends to
be clinically silent and is most often identified through
the incidental detection of hydronephrosis on abdomi-
nal imaging. Bilateral obstruction, acute or chronic,
presents with decreased urine output and signs and
symptoms of uremia.
13.8.2
Evaluation
Evaluation of the patient with suspected ureteral ob-
struction begins with a complete history and physical
examination. Laboratory evaluation includes a CBC,
a b
Fig. 13.4a–c.Distal ureteric obstruction in patient with locally recurrent cervical cancer. aAntegrade nephrostogramdemonstrat-
ing left hydronephrosis and hydroureter, indwelling ureteric stent is visualized within right ureter. b Obstruction visualized at
level of distal right ureter, no contrast within bladder.
serum electrolytes, BUN, creatinine, and urine culture.
Since patients with ureteral obstruction may require
the placement of percutaneous nephrostomy tubes, co-
agulation parameters should be routinely measured if
obstruction is suspected. It is of the utmost importance
to rule out the presence of concomitant urinary tract
infection. Fever and flank pain together with leukocy-
tosis and pyuria suggest urosepsis, a urologic emergen-
cy. Without prompt endoscopic or percutaneous de-
compression, obstructed urosepsis is a potentially le-
thal condition. Upper tract imaging should be per-
formed in all cases of suspected ureteral obstruction.
Available options include intravenous pyelography, ret-
rograde pyelography, antegrade pyelography, renal ul-
trasonography, radionuclide renography, and CT or
MRI of the abdomen and pelvis (Fig. 13.4). These stud-
ies can confirm the presence and site of obstruction
andmay also provide clues as to the etiology. In this re-
gard, CT and MRI provide the best anatomic detail of
the retroperitoneum and pelvis (Fig. 13.5). Upper tract
imaging can also establish the presence and severity of
obstructive uropathy. The finding of small atrophic
kidneys withmarked cortical thinning indicates chron-
ic obstruction (Fig. 13.6). Renal deterioration second-
ary to chronic obstruction is unlikely to improve with
decompression; therefore, intervention is reserved for
infected renal units (Logothetis et al. 2003).
13.8.3
Treatment
The management of malignant ureteral obstruction is
controversial and depends upon many factors includ-
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cFig. 13.4c. Ureteric stent placed beyond point of obstruction
a b
Fig. 13.5a, b. Distal ureteric obstruction in patient with locally recurrent cervical cancer. a CT demonstrating bilateral hydrone-
phrosis. b Posterior pelvic mass invading and displacing posterior bladder wall
ing oncologic prognosis, quality of life, and treatment-
related complications. Quite often, malignant ureteral
obstruction is a late presentation of advanced, incur-
ablemalignancy and portends a poor prognosis. In this
circumstance, the provision of ureteral decompression
is unlikely to improve either the quality or quantity of
life. The median survival of patients with active malig-
nancy who undergo renal decompression through in-
ternal or external drainage is only 3–7months (Wilson
et al. 2005; Donat and Russo 1996; Shekarriz et al.
1999). The only situation in which ureteral decompres-
sion is uniformly recommended is in the infrequent cir-
cumstance that an improvement in renal function will
facilitate the provision of therapeutic or palliative che-
motherapy (Russo 2000). Lymphoma and germ cell
cancer represent two such chemotherapy-sensitive ma-
lignancies wherein maximal preservation of renal
Fig. 13.6. Atrophic left kidney. Noncontrast CT demonstrating
left hydronephrosis and renal atrophy in patient with distal
ureteric obstruction
function is an important determinant of chemotherapy
delivery and ultimate success (Logothetis et al. 2003;
Ondrus et al. 2001).
Noninvasive treatment modalities, including retro-
grade internal ureteral stent (IUS) insertion and radiol-
ogy-guided percutaneous nephrostomy (PCN) inser-
tion, are most appropriate for malignant ureteral ob-
struction. It is difficult tomake a firm recommendation
in either regard since the quality of life they afford ap-
pears to be similar and both options have an equally
high complication rate (13%–63%) (Little et al. 2003;
Ganatra and Loughlin 2005; Donat and Russo 1996;
Shekarriz et al. 1999). Stent or PCN-related infection,
obstruction,migration, and dislodgement are common
and often necessitate prolonged hospitalization. In ex-
perienced hands, PCN drainage can be established in
98% of cases, with amajor complication rate of 4% (re-
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nal hemorrhage requiring transfusion, vascular injury,
sepsis, bowel injury, lung injury) and amortality rate of
0.05%–0.3% (Dyer et al. 1997; Stables 1982). Cysto-
scopic IUS insertion appears to have a higher initial
failure rate (15%–79%) than PCN, leading some au-
thors to propose that PCN should be the management
option of first choice in the acute setting (Ganatra and
Loughlin 2005; Chitale et al. 2002; Park et al. 2002).
Likewise, the accumulated incidence of recurrent ob-
structionmay be higher with IUS (11%) thanwith PCN
(1.3%) (Ku et al. 2004). Numerous studies have sought
to determine if tumor type, degree of hydronephrosis,
and level of obstruction are predictive of treatment fail-
ure; however, the results have thus far been contradic-
tory (Ganatra and Loughlin 2005). That being said,
some centers do recommend immediate PCN for ure-
teral obstruction secondary to advanced cervical can-
cer citing high failure rates with IUS in the short and
long term (Ku et al. 2004). Cystoscopic evidence of tu-
mor invasion appears to predict for IUS failure; there-
fore, radiographic imaging suspicious for involvement
of the bladder and ureteral orifice is an indication for
initial PCN. One-third of patients will ultimately fail
IUS within 6months and require long-term PCNdue to
repeat obstruction. Attempts to improve the long-term
success rates of IUS include frequent stent exchange
(every 3months) and the ipsilateral insertion of two in-
dwelling ureteral stents (two 7-F stents) (Ganatra and
Loughlin 2005; Rotariu et al. 2001). Periodic imaging to
confirm interval resolution or improvement of hydro-
nephrosis is also warranted in patients with IUS. De-
spite the relatively high failure rate of IUS,most author-
ities recommend a trial of retrograde ureteral stents in
all patients without obvious involvement of the distal
ureter and bladder (Ganatra and Loughlin 2005). Like-
wise, PCN tubes should be converted to IUS in an ante-
grade fashion after a period of renal decompression.
Situations in which retrograde stent insertion is advis-
able over PCN include those in which anatomic anoma-
lies present a technical challenge to PCN insertion (e.g.,
horseshoe kidney) or cases involving a solitary kidney
in which renal loss secondary to PCN-related renal
hemorrhage would be disastrous (Uthappa and Cowan
2005).
Decompression of solitary or bilaterally obstructed
kidneys may result in a postobstructive diuresis with
urine output in excess of 200 ml/ h. Most commonly,
this reflects the appropriate excretion of excess sodium,
urea, and water retained during the period of obstruc-
tion. Apart from the provision of oral fluids and the pe-
riodic evaluation of serum electrolytes, this form of di-
uresis requires no specific intervention. Serum creati-
nine and blood urea nitrogen typically normalize with-
in 48 h. On occasion, a pathologic diuresis involving
water or sodium-wasting may ensue secondary to sig-
nificant distal renal tubular damage. Vital statistics in-
cluding postural blood pressure measurements should
be performed on a frequent basis if a pathologic diure-
sis is suspected. These patients require careful moni-
toring and copious fluid replacement with 0.9% or
0.45% saline in order to avoid dehydration and electro-
lyte abnormalities.
In light of the significant long-term complication
rate associatedwithmechanical drainage, patients with
IUS or PCN require periodic monitoring with serum
creatinine, urine culture, and upper tract imaging. Ure-
teral stents and percutaneous nephrostomy tubes
should be exchanged every 3–4 months to prevent en-
crustation and obstruction. Depending on the chemo-
therapy or radiation-sensitivity of the etiologic malig-
nancy, mechanical drainagemay not be required indef-
initely. Most cases of extrinsic obstruction secondary
to germ cell or lymphomatous retroperitoneal lymph-
adenopathy will resolve with appropriate cytotoxic
chemotherapy (Logothetis et al. 2003). Likewise, up to
70% and 85% of patients with hormonally naı¨ve local-
ly advanced PCa treated with androgen ablation or ra-
diotherapy, respectively, will experience a relief of ob-
struction, obviating the need for mechanical drainage
(Michigan and Catalona 1977; Megalli et al. 1974).
Malignant ureteral obstruction is, in most cases, a
manifestation of advanced, incurable disease and por-
tends a poor prognosis. Even with the establishment of
mechanical internal or external drainage, the median
survival is 3–6 months among the most common etio-
logic malignancies. Furthermore, treatment-related
morbidity is high and patients can expect to spend a sig-
nificant portion of their remaining days in hospital
(18%–46%) (Little et al. 2003; Romero et al. 2005).
While IUS or PCN appear to be of questionable benefit
in the palliative setting, they retain utility in the treat-
ment of chemotherapy or radiation-sensitivemalignan-
cies. Clearly, this is a situation in which treatment, how-
ever minimally invasive it may be, should be ap-
proached in a cautious mannerand only after due con-
sideration has been given to the ultimate prognosis as
well as thewishes of a fully informed patient and family.
13.9
Bladder Outlet Obstruction
Acute urinary retention is not uncommon in cancer pa-
tients, particularly those with genitourinary malignan-
cies. Numerous etiologies exist and can be grouped into
two broad categories: (1)mechanical bladder outlet ob-
struction (BOO) and (2) neurophysiologic dysfunc-
tion. Localized growth of PCa is a common cause of
BOO. While symptomatic presentation is uncommon
today, up to 82% of patients with PCa in the pre-PSA
era presented with symptoms of urinary obstruction
(Brawn et al. 1994). Furthermore, up to 35% of PCa pa-
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tients placed on watchful waiting will eventually re-
quire transurethral prostatectomy (TURP) for symp-
tomatic progression or urinary retention (Whitmore et
al. 1991). Likewise, surgical and nonsurgical therapies
directed toward prostate cancer may predispose to uri-
nary retention. Bladder neck contracture (BNC) is re-
ported in 1.3%–27% of patients after radical prosta-
tectomy and 1.5%–22% of patients will develop uri-
nary retention following prostatic brachytherapy (An-
ger et al. 2005; Stone and Stock 2002).
Neurophysiologic bladder dysfunction may arise
secondary to medication side effects, postoperative
pain and immobility, radical pelvic surgery, and chron-
ic disease such as diabetesmellitus. Preexisting bladder
dysfunction is common among elderly patients and
evenminor insults can trigger urinary retention. Medi-
cations with anticholinergic, sympathomimetic, and
opioid activity are well known for their adverse effects
on bladder function in this regard and should be dis-
continued or substituted if possible. Up to 50% of pa-
tients undergoing abdominoperineal resection or radi-
cal hysterectomy will develop bladder dysfunction as a
result of interruption of parasympathetic innervation
(Eickenberg et al. 1976). Fortunately, urinary retention
secondary to radical pelvic surgery will spontaneously
resolve in up to 90% of patients thus affected.
13.9.1
Evaluation
The diagnosis of urinary retention is established rela-
tively easily. Patients typically complain of severe su-
prapubic pain and the inability to void. Physical exami-
nation often reveals a lower midline abdominal mass;
however, dullness with percussion of the lower abdo-
men may be a more sensitive sign of bladder fullness.
Apart from establishing urinary drainage, the next step
is to differentiate mechanical obstruction from neuro-
physiologic dysfunction. Pelvic and rectal examination
may identify a large obstructing pelvic tumor, while a
focused neurologic exam demonstrating sensory or
motor abnormalities may suggest a neurophysiologic
cause. Further enquiry should be made into baseline
voiding status, prior episodes of retention and associat-
ed treatment, overall health status, as well as the pres-
ence of medications or chronic illnesses known to un-
dermine bladder function. Since urinary tract infection
can complicate or precipitate urinary retention, the
presence of irritating voiding symptoms or fever
should be questioned. Renal insufficiency may compli-
cate longstanding or severe urinary retention; there-
fore, azotemia and associated electrolyte abnormalities
must be ruled out. Laboratory evaluation includes a
CBC, serum electrolytes, BUN, and serum creatinine.
Once urine becomes available, a urinalysis and urine
culture should also be performed. Imaging of the upper
tracts is indicated if renal dysfunction is present. Renal
size and cortical thickness may suggest the degree and
duration of obstruction and may also provide some
measure of salvageable renal function. Ultrasound ap-
pears to be the most cost-effective imaging modality in
this regard (Reisman et al. 1991).
13.9.2
Treatment
The first step in the management of urinary retention,
regardless of etiology, is bladder decompression
through the insertion of a urethral Foley catheter.
Should this prove difficult, attempts should be made to
insert a coude´-tipped catheter. Difficult catheterization
often indicates the presence of an obstructing process
such as urethral stricture or prostatic in-growth, be-
nign or malignant. Situations such as this may require
formal cystoscopy and possible urethral dilation for
catheter insertion. In the event that all attempts at cath-
eterization fail, the insertion of a suprapubic cystosto-
my tube is the most appropriate alternative. This can
usually be performed percutaneously at the bedside. A
history of lower abdominal or pelvic surgery is a con-
traindication to the percutaneous insertion of an su-
prapubic tube since intervening bowel may be injured.
In this circumstance, suprapubic drainage should be
established under radiologic guidance or in the operat-
ing room through open techniques.
Relief of longstanding bladder outlet obstruction
can result in a postobstructive diuresis. Thismost com-
monly reflects the appropriate excretion of retained so-
dium, water and urea; however, a concentrating defect
or a sodium-wasting nephropathy, both secondary to
distal renal tubular damage, may also play a role. Man-
agement is similar to that arising from upper tract ob-
struction.
Once bladder decompression has been achieved, fur-
ther management is dictated by the underlying patho-
logic process. Depending on the patient’s health and pri-
or voiding status, a trial of voiding is warranted in most
cases. Retention secondary to neurophysiologic bladder
dysfunction often resolves after a period of bladder de-
compression. Cases in which spontaneous voiding is
slow to return require the initiation of clean intermittent
catheterization every 4–6 h (Lapides et al. 1972). Inter-
mittent catheterization has demonstrated clear superi-
ority over chronic indwelling catheterization in terms of
preserving upper tract function andminimizing urinary
tract infection and stone formation. Benign prostatic
hypertrophy alone or together with neurologic dys-
function warrants a trial of [ -adrenergic blockade
(Flomax 0.4mg p.o. daily) and/or 5- [ -reductase inhibi-
tion (Finasteride 5 mg p.o. daily) therapy.
Locally advanced prostate cancer, not uncommonly,
precipitates urinary retention through compression of
13.9 Bladder Outlet Obstruction 163
the prostatic urethra and bladder neck. The most ap-
propriate initial therapy in the hormonally naı¨ve pa-
tient is androgen deprivation therapy. This may involve
either surgical (bilateral orchiectomy) or chemical cas-
tration (LHRH agonist). Although castrate levels of se-
rum testosterone are achieved much more rapidly with
bilateral orchiectomy (immediate) than with LHRH ag-
onist therapy (3–4 weeks), the reduction in prostate
and tumor volume is delayed with both, as is the ability
to spontaneously void. Two-thirds of patients thus treat-
ed will ultimately regain the ability to void; however,
roughly 50% of patients will require catheterization for
a period of 21–60 days in the interim (Fleischmann and
Catalona 1985). Temporary drainage can be achieved
through either continuous or intermittent catheteriza-
tion, depending on the ease of catheterization. Up to
22% of patients will develop urinary retention a mean
of 21 months after the initiation of hormonal therapy
(Sehgal et al. 2005). Prognostic factors for urinary re-
tention in this circumstance include a high Gleason
score (>7) and urinary retention at the start of hormon-
al therapy. Those cases that are unresponsive to andro-
gen deprivation or known to be resistant at baseline re-
quire TURP or intraprostatic urethral stenting. The in-
sertion of a urethral stent is most appropriate for those
patients who are poor surgical candidates and refuse an
indwelling catheter. As many as 88%–100% of patients
are able to void through a urethral stent with acceptable
morbidity out to 1 year (Ok et al. 2005; Guazzoni et al.
1994). Based on concerns over the risk of infection and
possible obstruction secondary to progressive tumor
growth, urethral stents are only recommended in pa-
tients with a limited life expectancy.
Palliative or channel TURP is the gold standard
treatment for PCa-related urinary retention unrespon-
sive to medical therapy. Although less successful and
associated with more complications than TURP per-
formed for BPH, palliative TURP is considered a safe
and efficacious procedure. Up to 79% of patients will
regain the ability to void despite the relatively high rate
of failure at initial trial of voiding (42%) (Crain et al.
2004). Morbidity is acceptable with an 8% transfusion
rate and negligible perioperativemortality rate. The re-
operation rate is relatively high (22%–29%) and likely
reflects less than complete resection (mean 12-g resec-
tion), continued local tumor growth, and the propensi-
ty of tumor to bleed (Mazur and Thompson 1991; Crain
et al. 2004). Photoselective vaporization of the prostate
(PVP) using high-power potassium-titanyl-phosphate
(KTP) laser energy is a relatively new procedure that
appears to be an acceptable alternative to standard
TURP for symptomatic obstructive uropathy second-
ary to either PCa or BPH (Sulser et al. 2004). Although
no randomized controlled trials have compared these
two modalities in the setting of PCa, similar improve-
ment in peak flow rates and urinary symptom scores
have been demonstrated in patients with BPH (Shing-
leton et al. 1999). Perceived advantages to PVP include
less bleeding, lower transfusion rate, shorter catheteri-
zation, and more rapid convalescence (Kumar 2005).
Chronic catheterization via an indwelling urethral
or suprapubic catheter is an option of last resort typi-
cally reserved for terminally ill patients or those who
fail medical and surgical therapies. Suprapubic cathe-
terization may be preferable to urethral catheterization
based on long-term data in spinal cord-injured pa-
tients, demonstrating lower rates of symptomatic uri-
nary tract infection and upper tract deterioration with
suprapubic drainage (Ku et al. 2005; Esclarin de Ruz et
al. 2000). To minimize catheter-related morbidity,
scheduled catheter changes should be conducted on a
monthly basis (Russo 2000). Chronic suppressive anti-
biotics are not recommended in catheterized patients
but short-course antibiotic therapy may be used at the
time of catheter exchange.
13.9.3
Urinary Retention After Prostatectomy
Prostate cancer treatment with curative intent can also
predispose to urinary retention. Although the true in-
cidence of bladder neck contracture following radical
prostatectomy is not known, 1.3%–27% of patients
will develop symptomatic BNC requiring treatment
(Anger et al. 2005). Surgical technique remains a criti-
cal determinant of BNC development; however, risk
factors for microvascular disease such as smoking, hy-
pertension, and diabetes mellitus also appear to play a
role (Borboroglu et al. 2000). Simple dilation appears to
be effective; however, some authors question the long-
term patency rates with such treatment. Transurethral
incision of the contracture using cold knife, electrocau-
tery, or the holmium:YAG laser is the most commonly
recommended treatment for severe BNC and those
cases involving urinary retention (Anger et al. 2005; Sa-
lant et al. 1990). Great care must be taken when per-
forming transurethral incision since deep incision may
cause sphincteric damage and, in turn, stress urinary
incontinence.
13.9.4
Urinary Retention After Brachytherapy
Urinary retention affects 1.5%–22% of men within a
median of 2 months following prostatic brachytherapy
(Stone and Stock 2002; Flam et al. 2004). Identified
preimplant risk factors include an International Pros-
tate Symptom Score above 20 and a prostate volume
larger than 35 cm3 (Terk et al. 1998; Gelblum et al.
1999). Attempts to reduce the risk of urinary retention
with prophylactic [ -adrenergic blockade (Flomax)
have thus far been unsuccessful (Elshaikh et al. 2005).
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The majority of cases respond to conservative mea-
sures such as catheter drainage plus or minus [ -block-
ade, those that do not require TURP. According to a re-
cent meta-analysis, up to 8.7% of brachytherapy pa-
tients undergo TURP after implantation; however,
large contemporary series report a lower rate of
1.1%–2% (Stone and Stock 2002; Allen et al. 2005;
Kollmeier et al. 2005). Urinary incontinence, while un-
common after TURP performed for BPH (1%–5%), is
reported in up to 70% of brachytherapy patients who
undergo TURP (Foote et al. 1991; Hu and Wallner
1998). The results of more recent series suggest the rate
of post-TURP incontinence is 0%–18% (Stone and
Stock 2002; Kollmeier et al. 2005). Radiation dose, pre-
implantation prostate volume, and hormonal therapy
do not appear to be predictive of subsequent inconti-
nence; however, TURP performedmore than 2 years af-
ter implant does appear to be a risk factor.
13.10
Respiratory Complications
13.10.1
Pulmonary Emboli
In urologic malignancies the primary respiratory com-
plication is fatal postoperative pulmonary emboli (PE)
(Fig. 13.7). The incidence of deep venous thrombosis
(DVT) and PE following urologic surgery in patients
without prophylaxis has been reported to be as high as
50% and 22%, respectively (Allgood et al. 1970; Mayo
et al. 1971). With the use of intermittent pneumatic
compression devices, the incidence of PE has decrease
to 2% (Igel et al. 1987; Leandri et al. 1992; Lepor and
Kaci 2003; Soderdahl et al. 1997). Scardino and others
at Baylor College of Medicine published an extensive
Fig. 13.7. Pulmonary embolism. Contrast-enhanced CT dem-
onstrating pulmonary embolism as large filling defect within
proximal right pulmonary artery in patient with renal cell car-
cinoma
review of published series reporting the perioperative
morbidity of radical prostatectomy (Dillioglugil et al.
1997). In a combined series of nearly 1,300 patients, the
mortality rate was 1.18%,with a PE incidence of 2.76%.
Controversy exists regarding the optimal DVT pro-
phylaxis for GU patients. The University College of
Dublin forwarded questionnaires to all urology resi-
dency programs in Ireland, the United Kingdom, and
the United States regarding the current practice with
respect to thromboprophylaxis (Galvin et al. 2004).
Among the three countries, there was no difference in
the use of nonpharmacological thromboprophylaxis,
with about 75% using either intermittent pneumatic
compression devices or support stockings. However;
just 24% of American urologists use pharmacological
thromboprophylaxis, such as conventional or low-mo-
lecular-weight heparin, in contrast to 100% of British
urologists.
There continues to be no consensus in regards to the
optimal DVT prophylaxis, though the minimum would
be the use of support stockings with either the addition
of compression devices or pharmacological thrombo-
prophylaxis.
13.10.2
Bleomycin Toxicity
Testicular cancer is unique in that cure often requires
an integration of chemotherapy and surgery. Treat-
ment of widely metastatic disease consists of cisplatin-
based chemotherapy, typically with three or four
courses of cisplatin, etoposide, and bleomycin. Those
patients not achieving radiographic response with re-
sidual retroperitoneal disease typically undergo post-
chemotherapy surgery. It is in this setting that the urol-
ogist must confront the potential postoperative pulmo-
nary toxicity related to bleomycin use.
Bleomycin exerts its cytotoxic effect by induction of
free oxygen radicals, resulting in DNA breaks and cell
death, as well as the inhibition of tumor angiogenesis.
Due to the lack of the bleomycin-inactivating enzyme,
bleomycin hydrolase, in the lungs and skin, bleomycin-
induced toxicity occurs predominately in these organs.
A multi-institutional study involving 812 testis cancer
patients performed serial pulmonary function testing
to define pulmonary toxicity related to bleomycin ad-
ministration (de Wit et al. 2001). This study found a
median acute decline in carbonmonoxide diffusion ca-
pacity (DCLO) of 19% in patients who received a cu-
mulative dose of 270 units. Chronic decline in DCLO
has not been shown. The toxic death rate at this dose is
less than 0.2%, with no significant impairment in long-
term pulmonary function. At doses of 360 units, the
toxic death rate increased to 1%–2%.
Prior bleomycin exposure has been associated with
an increased risk of postoperative pulmonary compli-
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cations including fatal acute respiratory distress syn-
drome (ARDS). In the 1980s and early 1990s at our insti-
tution, the postoperative management of such patients
involved the judicious administration of postoperative
fluid preferring oliguria and prerenal creatinine rise to
the potential of ARDS. With clinical experience, im-
proved surgical technique with decreased blood loss and
operative time, we no longer limit post-operate hydra-
tion. Massively obese patients, those who have received
salvage chemotherapy, or have extensive surgical dissec-
tions are at higher risk of postoperative pulmonary com-
plications and we would recommend judicious fluid ad-
ministration with monitoring of volume status.
13.10.3
Pulmonary Metastases
On rare occasions, patients with germ cell tumors may
present with respiratory compromise secondary to
massive pulmonary metastases. In this circumstance,
systemic chemotherapy is initiated on an emergent ba-
sis in lieu of radical orchiectomy. Although most pa-
tients would likely tolerate a primary orchiectomy, re-
spiratory failure represents the most immediate threat
to life and warrants directed therapy as such. Radical
orchiectomy is generally performed within a few weeks
of initiating chemotherapy.
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